Dimension-based separation to dissociate fixed tissue
By using microfluidic size sorting technology, the problem of separating tumor cells from normal cells has been solved, enabling efficient enrichment of tumor cells and generation of representative sequencing samples, reducing sequencing costs and simplifying the analysis process.
Patent Information
- Application Number
- CN202410833605.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-04-14
- Filing Date
- 2018-04-06
- Publication Date
- 2024-11-19
AI Technical Summary
Existing technologies struggle to effectively separate and enrich tumor cells from normal cells, resulting in wasted readings on normal DNA during tumor tissue sequencing, increasing costs and reducing sequencing efficiency, and making flow cytometry analysis difficult.
Microfluidic devices were used to separate tumor cells from normal cells through size sorting technology. By utilizing microfluidic devices such as deterministic lateral displacement, hydrophoretic filtration, and hydrodynamic filtration, cell size sorting and enrichment were achieved, avoiding the staining step and improving the representativeness and efficiency of sequencing.
It achieves efficient separation and enrichment of tumor cells and normal cells, reduces sequencing costs, improves the representativeness of sequencing and the accuracy of flow cytometry analysis, and simplifies downstream analysis procedures.
Smart Images

Figure CN118980553A_ABST
Abstract
Description
[0001] This invention application is a divisional application based on an invention patent application with an application date of April 6, 2018, application number 201880024764.0 (international application number PCT / EP2018 / 058809) and name “Size-based separation of dissociated fixed tissues”.
[0002] Cross-reference to related applications
[0003] This application claims the benefit of the filing date of U.S. Provisional Patent Application No. 62 / 485,550, filed on April 14, 2017, the disclosure of which is hereby incorporated by reference in its entirety. Background Art
[0004] Cancer is a disease marked by the uncontrolled proliferation of abnormal cells. In normal tissues, cells divide and organize within the tissue in response to signals from surrounding cells, resulting in normal cellular behavior that is carefully coordinated by the tissue context. Cancer cells do not respond to growth-restricting background cues from the surrounding tissues, and they often contain genetic alterations that drive them to proliferate and form tumors in many organs. As tumor growth progresses, genetic and phenotypic changes continue to accumulate, allowing the cancer cell population to overcome additional "checkpoints," such as anti-tumor immune responses, and exhibit a more aggressive growth phenotype of cancer cells. If left untreated, metastasis may occur, with cancer cells spreading to distant areas of the body via the lymphatic system or bloodstream. Metastasis leads to the formation of secondary tumors at multiple sites, damaging healthy tissue. Most cancer deaths are caused by such secondary tumors.
[0005] Despite decades of advances in cancer diagnosis and treatment, many cancers are not detected until late in their development. As a result, many solid tumors at the site of initial growth contain genetically and / or phenotypically heterogeneous tumor cell populations that are often spatially segregated. One or more of these cancer cell populations within the primary tumor may give rise to secondary metastatic tumors. In addition, the tumor mass is often composed of normal cells that are either recruited by the tumor to form a supportive environment (e.g., blood vessels) or are initially attracted to the tumor by the host as a defense mechanism (e.g., immune cells), but are later overcome as the cancer evolves. Summary of the invention
[0006] In one aspect of the present disclosure is a method for separating cell particles from a tissue sample, comprising: (i) homogenizing a tissue sample to provide a homogenized tissue sample; (ii) dissociating the homogenized sample into discrete unit cell particles; and (iii) sorting the cell particles within the homogenized tissue sample into at least a first cell particle population and a second cell particle population, wherein the difference in the size distribution of the two populations forms the underlying basis for their separation. In some embodiments, the sorting of cell particles is achieved using a microfluidic device. In some embodiments, no staining is performed before sorting. In some embodiments, staining is performed before sorting (e.g., using antibody staining and then adding a secondary antibody linked to beads, which enhances the size difference). In some embodiments, the cell particles are cells, and wherein the first cell particle population comprises normal cells and the second cell particle population comprises tumor cells. In some embodiments, the normal cells have an average diameter of less than 12 μm and the tumor cells have an average diameter of greater than 12 μm. In some embodiments, the tumor cells are derived from at least one of an intact tumor, a partial tumor, a metastatic tumor, a partial metastatic tumor, or a lymph node.
[0007] In some embodiments, the cell particles are nuclei, and wherein the first population of cell particles comprises normal nuclei and the second population of cell particles comprises tumor nuclei. In some embodiments, the normal nuclei have an average diameter of less than 8.5 μm and the tumor nuclei have an average diameter of greater than 8.5 μm.
[0008] In some embodiments, the tissue sample is derived from at least one of residual surgical material or a biopsy sample. In some embodiments, the tissue sample is a tissue sample fixed in a cross-linking solution. In some embodiments, the tissue sample is derived from a fixed sample embedded in paraffin. In some embodiments, the homogenized sample is further processed before sorting, wherein the further processing comprises at least one of digesting proteins within the homogenized sample, heating the sample, or filtering the homogenized sample.
[0009] In some embodiments, a microfluidic device is used to separate a population of cell particles. In some embodiments, the microfluidic device is a deterministic lateral displacement device. In some embodiments, the microfluidic device is a hydrophoretic filtration device. In some embodiments, the microfluidic device is a hydrodynamic filtration device. In some embodiments, the microfluidic device utilizes inertial focusing in a curved channel. In some embodiments, the microfluidic device utilizes inertial focusing in a straight channel. In some embodiments, inertial focusing in a straight channel comprises one of a narrow flow fractionation process or a hydrodynamic diffusion process.
[0010] In some embodiments, the method further comprises the step of determining a first biomarker for cell particles within the first or second cell particle population. In some embodiments, the presence of the first biomarker indicates cancer, or otherwise provides information about the clinical progression of a cancer patient. In some embodiments, the first biomarker is an immune cell marker. In some embodiments, the method further comprises analyzing RNA biomarkers for the first and second cell particle populations. For example, RNA expression analysis of a first cell particle population comprising primarily normal cells can be used to identify the type of immune cell population found in infiltrating immune cells. In some embodiments, the method further comprises analyzing protein biomarkers for the first and second cell particle populations.
[0011] In some embodiments, each of the first and second cell particle populations is independently sequenced using next generation sequencing. In some embodiments, each of the first and second cell particle populations is independently analyzed using flow cytometry. In some embodiments, the first and second cell particle populations provide matched tumor and normal samples for patients. In some embodiments, matched tumor and normal samples are analyzed to identify somatic mutations, copy number variations, or other genetic changes.
[0012] In another aspect of the present disclosure is a method of separating cells from a tissue sample, comprising: homogenizing a tissue sample to provide a homogenized tissue sample; and sorting cells in the homogenized sample by size using a sorting device, wherein the cells are sorted into at least a first and a second cell population, the first cell population being enriched for cells having an average diameter ranging from about 5 μm to about 12 μm, and the second cell population being enriched for cells having an average diameter ranging from about 12 μm to about 50 μm. In some embodiments, the first cell population is enriched for non-tumor cells, and wherein the second cell population is enriched for tumor cells.
[0013] In some embodiments, at least 80% of the cells in the first cell population have an average diameter ranging from about 5 μm to about 12 μm, and wherein at least 80% of the cells in the second cell population have an average diameter ranging from about 12 μm to about 50 μm (i.e., sorting via the device produces a sample containing 80% of the target population). In some embodiments, at least 90% of the cells in the first cell population have an average diameter ranging from about 5 μm to about 12 μm, and wherein at least 90% of the cells in the second cell population have an average diameter ranging from about 12 μm to about 50 μm.
[0014] In some embodiments, the first or second cell population is rare (less than 10%), and a successful outcome of sorting is enriching the population to at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80%. In some embodiments, sorting drives the percentage amount of any target population to double (e.g., enriching the target population from about 20% to about 40%).
[0015] In some embodiments, each of at least the first and second cell populations is independently sequenced using next generation sequencing. In some embodiments, at least the first and second cell populations provide matched tumor and normal cell samples for a patient. In some embodiments, matched tumor and normal cells are analyzed to identify somatic mutations, copy number variations, or other genetic changes.
[0016] In some embodiments, the tissue sample is derived from a complete tumor, a partial tumor, and / or a lymph node. In some embodiments, the tumor sample is derived from residual surgical material or a biopsy sample. In some embodiments, the tumor sample is derived from a sample embedded in paraffin. In some embodiments, the tissue sample is a fixed tissue sample, a fresh tissue sample, or any combination thereof.
[0017] In some embodiments, the homogenized tissue sample is further processed before sorting. In some embodiments, the further processing comprises the steps of digesting proteins within the homogenized sample and filtering the homogenized sample.
[0018] In some embodiments, the sorting device is a microfluidic device. In some embodiments, the microfluidic device is a deterministic lateral displacement device. In some embodiments, cells with a critical diameter of less than about 12 μm in a homogenized tissue sample move with the convection of the fluid passing through the device, while cells with a critical diameter of greater than about 12 μm in a homogenized sample move in a direction specified by the arrangement of the array. In some embodiments, nuclei with a critical diameter of less than about 8.5 μm in a homogenized tissue sample move with the convection of the fluid passing through the device, while nuclei with a critical diameter of greater than about 8.5 μm in a homogenized sample move in a direction specified by the arrangement of the array. In some embodiments, the microfluidic device is a hydrophoretic filtration device. In some embodiments, the microfluidic device is a hydrodynamic filtration device. In some embodiments, the microfluidic device employs inertial focusing in a curved channel. In some embodiments, the microfluidic device employs inertial focusing in a straight channel. In some embodiments, inertial focusing in a straight channel comprises one of a narrow flow fractionation process or a hydrodynamic diffusion process. In some embodiments, the sorting device does not require a step to stain the cells or nuclei.
[0019] In some embodiments, the method further comprises the step of determining a first biomarker for cells within the first or second population. In some embodiments, the first biomarker is a biomarker that, if present, indicates cancer. In some embodiments, the first biomarker is an immune cell marker. In some embodiments, the method further comprises analyzing RNA biomarkers for the first and second cell particle populations. In some embodiments, the method further comprises analyzing protein biomarkers for the first and second cell particle populations.
[0020] In another aspect of the present disclosure is a method of separating cells from a fresh tissue sample, comprising: homogenizing the fresh tissue sample to provide a homogenized tissue sample; sorting the cells in the homogenized tissue sample by size using a sorting device, wherein the cells are sorted into at least a first and a second cell population, the first cell population being enriched for cells having an average diameter ranging from about 6 μm to 12 μm, and the second cell population being enriched for cells having an average diameter greater than 12 μm. In some embodiments, staining is performed prior to sorting. In some embodiments, staining is not performed prior to sorting.
[0021] In some embodiments, the sorting device is a microfluidic device. In some embodiments, the microfluidic device is a deterministic lateral displacement device. In some embodiments, cells in a homogenized sample having a critical diameter of less than about 6 μm move with the convection of the fluid passing through the device, while cells in a homogenized sample having a critical diameter of greater than about 6 μm move in a direction specified by the arrangement of the array. In some embodiments, the microfluidic device is a hydrophoretic filtration device. In some embodiments, the microfluidic device is a hydrodynamic filtration device. In some embodiments, the microfluidic device utilizes inertial focusing in a curved channel. In some embodiments, the microfluidic device utilizes inertial focusing in a straight channel. In some embodiments, inertial focusing in a straight channel comprises one of a narrow flow fractionation process or a hydrodynamic diffusion process. In some embodiments, the sorting device does not require a step of staining the cells.
[0022] In another aspect of the present disclosure is a method for sequencing genomic material within a sample, comprising: homogenizing a tissue sample to provide a homogenized tissue sample; and sequencing at least a first population of cells or cell nuclei derived from the homogenized tissue sample, enriched for tumor cells or tumor nuclei. In some embodiments, cells or cell nuclei within the homogenized tumor sample are sorted using a microfluidic device to provide two populations of cells or cell nuclei. In some embodiments, at least 70% of the cells or cell nuclei within the first cell population are tumor cells. In some embodiments, at least 70% of the cells or cell nuclei within the first cell population have a size greater than 12 μm (cell) or 8.5 μm (nuclei). In some embodiments, at least 80% of the cells or cell nuclei within the first cell population are tumor cells or tumor nuclei.
[0023] In some embodiments, cells or cell nuclei derived from a homogenized tissue sample are sorted according to their hydrodynamic size. In some embodiments, cells or cell nuclei are sorted using a microfluidic device. In some embodiments, the microfluidic device does not require staining of the cells or cell nuclei prior to sorting. In some embodiments, the microfluidic device employs one of deterministic lateral displacement, hydrophoretic filtration, hydrodynamic filtration, inertial focusing in a curved channel, and inertial focusing in a straight channel.
[0024] In some embodiments, the first cell or cell nucleus population comprises at least 0.05 micrograms of genomic material for sequencing. In some embodiments, the first cell or cell nucleus population comprises at least 0.1 micrograms of genomic material for sequencing. In some embodiments, the first cell or cell nucleus population comprises at least 0.5 micrograms of genomic material for sequencing. In some embodiments, the sequencing method comprises up to 4 amplification cycles before sequencing. In some embodiments, the sequencing method comprises up to 6 amplification cycles before sequencing. In some embodiments, the sequencing method comprises up to 8 amplification cycles before sequencing. In some embodiments, no amplification cycles before sequencing are required.
[0025] In another aspect of the present disclosure is a method of deriving an enriched population of tumor nuclei and an enriched population of normal nuclei from a tumor sample, comprising dissociating tumor and normal nuclei from a tumor sample; and sorting the tumor and normal nuclei by size using a microfluidic sorting device, wherein the microfluidic sorting device does not require a staining or biomarker analysis step prior to sorting. In some embodiments, the enriched population of tumor nuclei comprises at least 85% tumor nuclei; and wherein the enriched population of normal nuclei comprises at least 85% normal nuclei. In some embodiments, the tumor nuclei within the enriched population of tumor nuclei comprise an average nuclear size greater than 8.5 μm. In some embodiments, the normal nuclei within the enriched population of normal nuclei comprise an average nuclear size less than 8.5 μm. In some embodiments, sorting drives the percentage amount of any target population to double (e.g., enriching the target population from about 20% to about 40%).
[0026] In some embodiments, the method further comprises the step of sequencing the enriched population of tumor nuclei and the enriched population of normal nuclei separately. In some embodiments, at least one of somatic mutations, copy number variations, or other genetic changes is identified in the enriched population of tumor nuclei.
[0027] In some embodiments, the tumor sample is derived from a complete tumor, a portion of a tumor, one or more lymph nodes, and / or a sample embedded in paraffin. In some embodiments, the tumor sample comprises freshly dissociated tissue.
[0028] In another aspect of the present disclosure is a method for treating cancer by identifying a subtype of cancer that is responsive to a particular treatment or active pharmaceutical ingredient, wherein the subtype of cancer is identified by sequencing a sample enriched in tumor cells, wherein the sample is enriched in tumor cells or tumor nuclei by homogenizing an input tissue (e.g., a sample comprising at least one of a tumor, one or more lymph nodes, or blood); and sorting tumor cells or tumor nuclei from normal cells or normal nuclei in the homogenized sample using a size-based sorting device, and wherein the size-based sorting device does not require staining of the tumor cells or tumor nuclei prior to sorting. In some embodiments, staining is performed prior to sorting. In some embodiments, the cell population enriched in tumor cells or tumor nuclei contains sufficient genomic material to allow up to four cycles of amplification prior to sequencing.
[0029] In some embodiments, up to 2 amplification cycles are performed prior to sequencing. In some embodiments, the amount of genomic material is at least 0.01 micrograms. In some embodiments, the amount of genomic material is at least 0.1 micrograms. In some embodiments, the amount of genomic material is at least 0.2 micrograms. In some embodiments, the amount of genomic material is at least 0.5 micrograms. In some embodiments, after identifying a cancer subtype, a course of treatment is provided to the patient from whom the sample was derived. In some embodiments, the size-based sorting device does not require any step of staining prior to sorting. In some embodiments, staining is performed prior to sorting.
[0030] In another aspect of the present disclosure is a method for treating cancer by identifying somatic mutations in tumor cells or tumor nuclei, comprising homogenizing a tissue sample derived from a patient; dissociating cells within the homogenized tissue sample; and separating tumor cells or tumor nuclei from normal cells or normal nuclei in the dissociated tissue sample using a microfluidic device to provide a first population, which is enriched in tumor cells or tumor nuclei, having an average diameter ranging from about 5 μm to about 12 μm (cells) or 4 μm to about 8.5 μm (nuclei), and a second population, which is enriched in normal cells or normal nuclei, having an average diameter ranging from about 12 μm to about 50 μm (cells) or 8.5 μm to about 25 μm (nuclei), wherein the microfluidic device does not require staining or labeling before sorting. In some embodiments, the microfluidic device employs one of deterministic lateral displacement, hydrophoretic filtration, hydrodynamic filtration, inertial focusing in a curved channel, and inertial focusing in a straight channel. In some embodiments, the cell population is enriched without first staining the cells.
[0031] In another aspect of the present disclosure is a method of separating cells, nuclei, or tissue aggregates from a tissue sample to facilitate downstream analysis, comprising: separating cells, nuclei, or tissue aggregates from a tissue sample to provide a separated sample; sorting the cells, nuclei, or tissue aggregates in the separated sample by size using a sorting device, wherein the cells, nuclei, or tissue aggregates are sorted into a first and a second population, the first population having a first cell, nucleus, or tissue aggregate average diameter and the second population having a second cell, nucleus, or tissue aggregate average diameter. In some embodiments, the sorting device is a microfluidic device. In some embodiments, the microfluidic device employs one of deterministic lateral displacement, hydrophoretic filtration, hydrodynamic filtration, inertial focusing in a curved channel, and inertial focusing in a straight channel. In some embodiments, the method further comprises the step of performing a genomic analysis on at least one of the first or second populations. In some embodiments, the method further comprises the step of performing a flow cytometric analysis on at least one of the first or second populations. In some embodiments, the method further comprises the step of staining at least one of the first or second populations for the presence of at least one biomarker.
[0032] In another aspect of the present disclosure is a composition enriched for tumor cells, the tumor cells having a size greater than 12 μm, wherein the tumor cells are separated from normal cells without first staining the tumor or normal cells. In another aspect of the present disclosure is a composition enriched for tumor nuclei, the tumor nuclei having a size greater than 8.5 μm, wherein the tumor nuclei are separated from normal nuclei without first staining the tumor or normal nuclei. In some embodiments, at least 40% of the composition comprises tumor cells or nuclei. In some embodiments, at least 50% of the composition comprises tumor cells or nuclei. In some embodiments, at least 60% of the composition comprises tumor cells or nuclei. In some embodiments, at least 70% of the composition comprises tumor cells or nuclei. In some embodiments, at least 80% of the composition comprises tumor cells or nuclei. In some embodiments, at least 90% of the composition comprises tumor cells or nuclei. In some embodiments, at least 95% of the composition comprises tumor cells or nuclei. In some embodiments, the tumor population is rare (less than 10%), and the composition after sorting enriches the population to at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80%. In some embodiments, the composition of the enriched sample is double the initial percentage of the tumor population.
[0033] In another aspect of the present disclosure, a kit comprising a first cell population and a second cell population, the first cell population being substantially enriched for tumor cells having a size greater than 12 μm, the second cell population being substantially enriched for normal cells having a size less than 12 μm, the first and second cell populations being derived from the same tumor sample, and wherein the tumor cells and normal cells are unstained. In another aspect of the present disclosure, a kit comprising a first nuclear population and a second nuclear population, the first nuclear population being substantially enriched for tumor nuclei having a size greater than 8.5 μm, the second nuclear population being substantially enriched for normal nuclei having a size less than 8.5 μm, the first and second nuclear populations being derived from the same tumor sample, and wherein the tumor nuclei and normal nuclei are unstained.
[0034] Current diagnostic tools face significant obstacles in adequately representing the genetically heterogeneous cancer cells and different cell types that make up the tumor mass, primarily because current tumor sampling protocols use only a small, localized portion of each tumor for all diagnostic tests. Applicants have developed a new approach to tumor sampling that allows for meaningful information to be derived from the sampled tumor. As detailed herein, achieving this goal allows for a more accurate snapshot of the changes driving cancer, better treatment approaches for patients, and better predictions of potential mechanisms of treatment resistance.
[0035] It is believed that separating and sorting cells from complex, heterogeneous mixtures represents a critical task in many fields of biology, biotechnology, and medicine. Indeed, it is believed that different tumors have different percentages of tumor cells and normal cells. As a result, it is believed that sequencing a representative sample from a tumor with a higher percentage of contaminating normal tissue (e.g., due to immune infiltration) is more expensive because a portion of the reads will be "wasted" on normal DNA. As used herein, "read" refers to the sequence of a cluster obtained after the sequencing process is completed, which is ultimately the sequence of a segment of a unique fragment of a fragmented nucleic acid sequence. Current clinical sequencing from tumor tissue volumes (from blocks) also unintentionally wastes reads on contaminating normal tissue (as used herein, "tissue volume" refers to a tissue section of a defined thickness cut from an FFPE block, usually with a microtome). As such, it is believed that the mixture of tumor and normal (immune) cells in both representative samples and archived tissue samples (from blocks) poses a challenge to tumor tissue sequencing.
[0036] In addition, it is often important to sequence separate non-malignant tissue sources from the same patient to define true somatic mutations in addition to genetic polymorphisms present in non-malignant tissues. For archived tumor blocks, these non-malignant tissues may not have been collected. Moreover, there may be sequencing applications for which it is critical to separate immune components from tumor tissue. In view of this, it is necessary to enrich normal tissues from representative samples and tissue blocks.
[0037] The mixture of tumor cells and normal (immune) cells (which often express biomarkers unique to each type of tissue) also makes it more difficult to analyze dissociated representative samples by flow cytometry. It is believed that the ability to separate different cell types before downstream analysis will make it more straightforward to analyze dissociated fixed tissue samples by flow cytometry.
[0038] In view of the foregoing, the applicant has developed a sorting method whereby a heterogeneous mixture of tumor cell particles and normal cell particles can be enriched or purified into one or more well-defined populations (e.g., tumor populations or normal cell populations), thereby enhancing the efficiency of research, tumor analysis, and other downstream processing tasks (e.g., genome sequencing, FACS analysis, RNA or protein biomarker analysis). In some embodiments, the method developed by the applicant does not require staining or labeling of cells or nuclei before sorting, thus establishing a superior sorting method compared to fluorescence activated cell sorting (FACS) or methods using magnetic activated cell sorting (although staining can be used before sorting). Moreover, it is believed that the method of generating an enriched population of cell particles (e.g., cells or cell nuclei) according to the present disclosure allows for a reduction in the cost of genome sequencing. The applicant also believes that the method disclosed herein can be used to generate matched tumor and normal cell populations from a patient sample, such as from residual surgical material or extracted archived samples (from paraffin blocks).
[0039] Applicants have also found that the sorting device described herein facilitates providing matched tumor samples and normal samples for each patient, thereby enabling identification of true somatic mutations via sequencing, especially for archived samples lacking non-malignant tissue samples from the same patient. It is believed that the enrichment of tumor and normal populations can also reduce the cost of sequencing and potentially simplify analysis by flow cytometry. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 A flow chart illustrating a method according to one embodiment of the present disclosure is set forth.
[0041] Figure 2 A flow chart illustrating a method according to another embodiment of the present disclosure is listed.
[0042] Figure 3 A flow chart illustrating a method according to another embodiment of the present disclosure is listed.
[0043] Figure 4 A flow chart illustrating a method according to another embodiment of the present disclosure is listed.
[0044] Figure 5A Listed are the size distributions of nuclei prepared from representative colon adenocarcinoma tumor samples, with the figure showing Coulter counter analysis, using a moving average to smooth the trace. The Coulter method for sizing and counting particles is based on measurable changes in electrical impedance produced by non-conductive particles suspended in an electrolyte. Particles measured on a Coulter counter are grouped into bins of the same size (size bins). The size bin values reported on the horizontal axis refer to increasingly larger particle diameters. Using microscopic images, we empirically estimate that a size bin of about "50" roughly correlates to a diameter of about 6 μm; a size bin of about "100" roughly correlates to a diameter of about 9 μm, and a size bin of about "150" roughly correlates to a diameter of about 14 μm.
[0045] Figure 5B Listed are the size distributions of nuclei prepared from a representative lung squamous cell carcinoma tumor sample, the graph shows Coulter Counter analysis, with the trace smoothed using a moving average.
[0046] Fig. 6AA histogram of flow cytometry data of nuclei isolated from representative samples of colon tumors is provided and further illustrated that positive cytokeratin (CK) staining can distinguish tumor nuclei from normal nuclei. The left panel (i) represents CK staining intensity, visualized by TSA-rhodamine 101. Gates are established for CK positive and CK negative nuclei. The middle panels (ii and iii) represent DAPI staining intensity as a readout of the DNA content of the CK negative and positive populations defined by the gate in panel i. Note the single peak of DAPI staining intensity in panel (ii) (CK negative) and the multi-peak in panel iii (CK positive). The right panels (iv and v) show histograms of CK staining intensity of nuclei flow-sorted according to the gate determined in panel (i). Panel iv shows analysis of particles enriched as defined as CK negative, while panel v shows enrichment of those defined as CK positive.
[0047] Figure 6B A histogram of flow cytometry data of nuclei isolated from representative samples of lung tumors is provided and further illustrated that positive cytokeratin (CK) staining can distinguish tumor nuclei from normal nuclei. The left panel (i) represents CK staining intensity, visualized by TSA-rhodamine 101. Gates are established for CK positive and CK negative nuclei. The middle panels (ii and iii) represent DAPI staining intensity as a readout of the DNA content of the CK negative and positive populations defined by the gate in panel i. Note the single peak of DAPI staining intensity in panel (ii) (CK negative) and the multi-peak in panel iii (CK positive). The right panel (iv and v) shows a histogram of CK staining intensity of nuclei flow-sorted according to the gate determined in panel (i). Panel iv shows an analysis of particles enriched as defined as CK negative, while panel v shows the enrichment of those defined as CK positive.
[0048] Fig. 7A Listed are the size distributions of nuclei sorted from representative colon adenocarcinoma tumor samples. The figure shows Coulter counter analysis, using moving average to smooth the trace. The dot trace corresponds to unsorted nuclei; the dashed trace corresponds to cytokeratin (CK) negative nuclei sorted using FACS; the solid trace corresponds to cytokeratin (CK) positive nuclei sorted using FACS.
[0049] Figure 7B Listed are the size distributions of nuclei sorted from a representative lung squamous cell carcinoma tumor sample. The figure shows Coulter counter analysis, using moving average to smooth the traces. The dot trace corresponds to unsorted nuclei; the dashed trace corresponds to cytokeratin (CK) negative nuclei sorted using FACS; the black trace corresponds to cytokeratin (CK) positive nuclei sorted using FACS.
[0050] Figure 8The distribution of single cells extracted from representative tumor samples is listed. The figure shows single cells dissociated from colon tumors (top), single cells dissociated from tonsils (bottom), and Coulter counter analysis of EpCAM-positive cells dissociated from colon tumors and then sorted by FACS.
[0051] Fig. 9 The size distribution of cells dissociated from formalin-fixed tonsils (black trace) and formalin-fixed, paraffin-embedded tonsils (grey trace) is shown. The graph shows the Coulter Counter analysis, with the traces smoothed using a moving average.
[0052] Fig.10 Illustration of cell sorting by constriction flow fractionation. A) In the constriction, cells are first pushed toward the wall and then separated by size as the microfluidic channel widens. B) Cells align in the constriction of the channel and follow separate streamlines after leaving the constriction to be sorted by size.
[0053] Fig.11 Illustration of cell sorting by deterministic lateral displacement. Due to the engineered size and spacing of the microposts in the microfluidic channel, large cells (depicted in blue) migrate away from small cells (depicted in red) in the initial streamline.
[0054] Fig.12 Illustration of cell sorting by hydrodynamic filtration. A) Cells are injected into the microfluidic device and pushed toward the outlet. B) Small cells exit through the proximal branch and C) large cells exit through the distal branch.
[0055] Fig.13A A method of geometrically directional scrolling in a hydrodynamic filtration device comprising a main channel and multiple side channels is shown.
[0056] Fig. 13B Provides a close-up view of the flow velocity distribution at the branch between the main channel and the side channel.
[0057] Fig. 13C Another microfluidic device contemplated for use within the presently disclosed methods is illustrated. The Vortex HE device disclosed herein has 8 reservoirs in series and 8 in parallel. (a) Initially cells are distributed throughout the channel cross section. (b) After traveling a predetermined distance, larger cells (e.g., tumor cells) that experience greater inertial lift migrate toward the channel wall. (c) Larger cells (e.g., tumor cells) located near the wall experience sufficient lift to enter the reservoir and remain stably captured, while smaller cells (e.g., normal cells) either do not enter the reservoir or do not remain captured and return to the mainstream.
[0058] Fig.14 Shown are the distributions of relative cell sizes for colon and lung tumor samples.
[0059] Fig.15A Illustration of sequencing data for a FACS-enriched tumor sample, where large cells were identified as tumor cells based on elevated allele fractions of clonal tumor mutations. Here, the Coulter Counter trace shows the relative sizes of unsorted and FACS-enriched tumor nuclei from a colon adenocarcinoma.
[0060] Fig. 15B Illustration of sequencing data from a FACS-enriched tumor sample, where large cells were identified as tumor cells based on elevated allele fractions of clonal tumor mutations. Here, bar graphs show representative samples of colon tumor homogenates (unsorted) and FACS-sorted tumor nuclei (CK positive) (from Fig.15A )’s sequencing data.
[0061] Fig. 15C The sequencing data of FACS-enriched tumor samples are shown, where large cells are identified as tumor cells based on the elevated allele fraction of clonal tumor mutations. Here, tumor mutations were detected in both bulk representative sample homogenates and FACS-sorted tumor nuclei (n=351). In addition, some tumor mutations were detected in FACS-sorted nuclei only (n=68) and homogenates only (n=6). The greater detection of tumor mutations in FACS-sorted nuclei indicates that the sensitivity of the genomic assay is improved due to the enrichment of tumor nuclei.
[0062] Fig.15D Graph showing sequencing data for a FACS-enriched tumor sample, where large cells were identified as tumor cells based on elevated allele fractions of clonal tumor mutations. The graph shows the allele frequencies of two clonal drivers in homogenate versus FACS-sorted nuclei. Note that for FACS-sorted tumor nuclei, the mutant allele frequency (MAF%) is close to 50%, which is the upper limit expected for dominant clonal driver mutations.
[0063] Fig.16A Bright field images of nuclei isolated from fixed tonsil tissue are provided. The inset of the diagram shows the nuclei at increasing magnifications. The lower inset shows the mask (black outline) used for area calculation in ImageJ. The scale bar is 100 μm.
[0064] Fig. 16B A graph showing the size range calculated using images of tonsil nuclei in (A) and tumor nuclei from ovarian tumors containing greater than 80% tumor content is provided. The average size of the tonsil nuclei was calculated to be 6.7 μm, while the average size of the tumor nuclei was 13.0 μm. A cutoff of 8.5 μm would allow separation of the two populations.
[0065] Fig. 16CA graph showing the size range calculated using images of tonsil cells and tumor cells from a colon cancer containing approximately 40% tumor cell content (measured by flow cytometry, not shown) is provided. The average size of the tonsil cells was calculated to be 8.7 + / - 1.5 μm, while the average size of cells in the colon tumor sample consisting of approximately 40% tumor cells, 60% normal cells was 12.0 + / - 4.2 μm. Assuming that normal cells follow the size distribution of tonsil cells, a cutoff of approximately 12 μm would allow for enrichment of tumor cells. Supporting this, 40% of the cells in the colon tumor sample were 12 μm or larger. DETAILED DESCRIPTION
[0066] Overview
[0067] In general, the present disclosure provides a method for separating or isolating cell particles (e.g., cells, nuclei) and / or small tissue aggregates from a tissue sample (e.g., a tumor sample, a lymph node sample, etc.) (step 100), and then sorting the cell particles and / or small tissue aggregates into two or more populations (e.g., a tumor cell particle population, a normal cell particle population), such as by size or hydrodynamic size (step 110), so that each cell particle population and / or small tissue aggregate can be analyzed (step 120) (see Figure 1 ). As such, the present disclosure enables a method for fractionating fixed dissociated tissue upstream of sequencing and / or protein or RNA biomarker analysis. In some embodiments, each cell particle population or its sorted fraction is enriched for a specific type of cell particles (e.g., tumor cells, normal cells, tumor nuclei, normal nuclei) or tumor tissue aggregates or normal tissue aggregates.
[0068] The present disclosure also provides devices, such as microfluidic devices, for enriching and analyzing subpopulations of tumor cell particles and normal cell particles (e.g., tumor cells, normal cells, tumor nuclei, normal nuclei), and methods of using such devices. In some embodiments, the devices of the present disclosure incorporate arrays, such as arrays of obstacles, which allow displacement of cells, nuclei, or tissue aggregates of predetermined sizes, thereby providing a mechanism to provide samples enriched in certain cell populations, nuclei, or tissue aggregates. In some embodiments, the size of the array is determined according to the size typically associated with normal cells or tumor cells, such as disclosed herein.
[0069] The present disclosure further provides a method of diagnosing a condition, such as cancer, in a subject by analyzing a sample from the subject (step 120), wherein the sample is separated from tissue (step 100), then sorted (step 110), such as with a microfluidic sorting device, and then analyzed (step 120). In some embodiments, the present disclosure provides a method of analyzing cancer cells or nuclei in a cell sample by introducing the cell sample into a device having at least one channel, the channel comprising a structure that directs cancer cells or nuclei in a first direction to produce a first output sample enriched in cancer cells or nuclei and directs non-cancer cells or nuclei in a second direction to produce a second output sample enriched in non-cancer cells or nuclei; and performing an analysis, such as a genomic analysis, on a population enriched in cancer cells or nuclei. In some embodiments, genomic analysis is performed on both cancer and non-cancer cell or nuclei populations.
[0070] In some embodiments, the method allows for providing tumor-enriched tissue that matches enriched normal tissue, thereby reducing sequencing costs and enabling bioinformatics analysis.
[0071] definition
[0072] It should also be understood that, in any method claimed herein that includes more than one step or action, the order of the method steps or actions is not necessarily limited to the order in which the method steps or actions are described unless clearly indicated to the contrary.
[0073] As used herein, the singular terms "a", "an", and "the" include plural referents unless the context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise. The term "comprising" is defined to be inclusive, such that "comprising A or B" means comprising A, B, or A and B.
[0074] As used herein in the specification and claims, "or" shall be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" shall be interpreted as inclusive, i.e., including at least one item, but also including more than one item of some element or list of elements, and optionally additional unlisted items. Only when a term clearly indicates the contrary, such as "only one of" or "exactly one of", or when used in the claims, "consisting of..." will mean including exactly one element of some element or list of elements. In general, as used herein, the term "or" shall only be interpreted as indicating exclusive alternatives (i.e., "one or the other but not both") when accompanied by an exclusive term, such as "either", "one of", "only one of", or "exactly one of". When used in the claims, "consisting essentially of..." shall have its ordinary meaning as used in the field of patent law.
[0075] As used herein in the specification and in the claims, the phrase "at least one" when referring to a list of one or more elements should be understood to mean at least one element selected from any one or more elements in the list of elements, but not necessarily including at least one of each and every element specifically listed in the list of elements and not excluding any combination of elements in the list of elements. This definition also allows for the optional presence of elements other than the elements specifically identified in the list of elements to which the phrase "at least one" refers, whether related or unrelated to those specifically identified elements. Thus, as a non-limiting example, "at least one of A and B" (or equivalently "at least one of A or B" or equivalently "at least one of A and / or B") may refer in one embodiment to at least one, optionally including more than one A, B not present (and optionally including elements other than B); in another embodiment to at least one, optionally including more than one B, A not present (and optionally including elements other than A); in yet another embodiment to at least one, optionally including more than one A, and at least one, optionally including more than one B (and optionally including other elements); etc.
[0076] As used herein, the terms "comprising", "including", "having", and the like are used interchangeably and have the same meaning. Specifically, the definition of each term is consistent with the commonly used U.S. patent law definition of "comprising" and is therefore interpreted as an open-ended term, meaning "at least the following" and also interpreted as not excluding additional features, limitations, aspects, etc. Thus, for example, "a device having components a, b, and c" means that the device includes at least components a, b, and c. Similarly, the phrase "a method involving steps a, b, and c" means that the method includes at least steps a, b, and c. Moreover, although steps and processes may be outlined in a particular order herein, the skilled artisan will recognize that the order of steps and processes can be varied. As used herein, the term "amplification" refers to the process of multiplying the original amount of nucleic acid template to obtain a larger amount of the original nucleic acid.
[0077] Likewise, the term "amplification" refers to the process of replicating a portion of a nucleic acid using, for example, a plurality of primer extension reactions. Exemplary primer extension reactions include, but are not limited to, polymerase chain reaction (PCR). Unless otherwise specified, "amplification" refers to a single replication or arithmetic, logarithmic, or exponential amplification. In general, PCR is a method of increasing the concentration of a target sequence in a mixture of genomic DNA without cloning or purification. This process for amplifying a target sequence consists of introducing a large excess of two oligonucleotide primers into a DNA mixture containing the desired target sequence, followed by a precise sequence of thermal cycles in the presence of a DNA polymerase. The two primers are complementary to their respective strands in the double-stranded target sequence. To achieve amplification, the mixture is denatured and then the primers are annealed to their complementary sequences within the target molecule. After annealing, the primers are extended with a polymerase (e.g., a DNA polymerase) to form a new pair of complementary strands. The steps of denaturation, primer annealing, and polymerase extension can be repeated multiple times (i.e., denaturation, annealing, and extension constitute one "cycle"; there can be many "cycles") to obtain a high concentration of amplified segments (amplicons) of the desired target sequence. The length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, such length is a controllable parameter. The polymerase chain reaction ("PCR") is described, for example, in U.S. Pat. No. 4,683,202; U.S. Pat. No. 4,683,195; U.S. Pat. No. 4,000,159; U.S. Pat. No. 4,965,188; U.S. Pat. No. 5,176,995), the disclosures of each of which are hereby incorporated herein by reference in their entirety.
[0078] As used herein, the term "biological sample" or "tissue sample" refers to any sample including biomolecules (such as proteins, peptides, nucleic acids, lipids, carbohydrates, or combinations thereof) obtained from any organism, including viruses. Other examples of organisms include mammals (such as humans; veterinary animals, like cats, dogs, horses, cattle, and pigs; and laboratory animals, like mice, rats, and primates), insects, annelids, arthropods, marsupials, reptiles, amphibians, bacteria, and fungi. Biological samples include tissue samples (such as tissue sections and needle biopsies of tissue), cell samples (such as cytological smears, such as Pap smears or blood smears or samples of cells obtained by microdissection), or cell fractions, fragments or organelles (such as obtained by lysing cells and separating their components by centrifugation or other means). Other examples of biological samples include blood, serum, urine, semen, feces, cerebrospinal fluid, interstitial fluid, mucus, tears, sweat, pus, biopsy tissue (e.g., obtained by surgical biopsy or needle biopsy), nipple aspirate, cerumen, milk, vaginal fluid, saliva, swabs (such as cheek swabs), or any material containing biomolecules derived from a first biological sample. In certain embodiments, as used herein, the term "biological sample" refers to a sample (such as a homogenate or liquefied sample) prepared from a tumor or a portion thereof (obtained from a subject).
[0079] As used herein, the term "biomarker" refers to a biological molecule found in blood, other body fluids, or tissues as a sign of a normal or abnormal process, or a condition or disease (such as cancer). Biomarkers can be used to determine how well the body responds to treatment for a disease or condition or whether a subject is susceptible to a disease or condition. In the context of cancer, a biomarker refers to a biological substance that indicates the presence of cancer in the body. A biomarker can be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Such biomarkers can be measured in non-invasively collected biological fluids, like blood or serum. Several gene- and protein-based biomarkers have long been used in patient care, including but not limited to AFP (liver cancer), BCR-ABL (chronic myeloid leukemia), BRCA1 / BRCA2 (breast / ovarian cancer), BRAF V600E (melanoma / colorectal cancer), CA-125 (ovarian cancer), CA19.9 (pancreatic cancer), CEA (colorectal cancer), EGFR (non-small cell lung cancer), HER-2 (breast cancer), KIT (gastrointestinal stromal tumor), PSA (prostate-specific antigen), S100 (melanoma), etc. Biomarkers may be useful as diagnostics (for identifying early stage cancer) and / or prognostics (for predicting how aggressive a cancer is and / or predicting how a subject will respond to a particular treatment and / or how likely the cancer is to recur).
[0080] As used herein, the term "enriched sample" means a sample containing components that has been processed to increase the relative number (population) of the component of interest relative to other components typically present in the sample. In some embodiments, the methods disclosed herein utilize a device to enrich or sort at least one type of cell from other types of cells in a flow containing a mixture of cell types (e.g., tumor cells and normal cells). As used herein, the term "enrichment" (and similarly the terms "separation" or "sorting") does not mean that the enriched target cells, nuclei, or tissue aggregates are 100% separated from other non-target cells, nuclei, or tissue aggregates, but only means that the mixture has undergone some amount of enrichment compared to the starting mixture. For example, a sample may be enriched by increasing the relative population of cells of interest by a factor of at least 10%, 25%, 50%, 75%, 100%, or at least 10, 100, 1,000, 10,000, 100,000, 1,000,000, 10,000,000, or even 100,000,000.
[0081] As used herein, the term "cell particle" refers to an individual cell or an organelle released from a cell. In some embodiments, the organelle released from a cell is a nucleus. In other embodiments, the organelle released from a cell is a nucleus that contains remnants of cytoplasmic material that can be used to identify the cell of nuclear origin. For example, cytokeratin can remain attached to the nucleus and can be used as a protein marker for nuclei derived from tumor cells.
[0082] As used herein, the term "fixed" means that the tissue sample has been incubated in a cross-linking solution in order to preserve the cellular and / or structural integrity of the tissue sample. Common examples of cross-linking solutions include neutral buffered formalin, methanol, alcoholic formalin, Bouins, etc.
[0083] As used herein, the term "H&E" refers to staining with the primary dyes hematoxylin and eosin.
[0084] As used herein, the term "hydrodynamic size" means the effective size of a particle when interacting with a flow, an obstruction, or other particles. It is used as a general term for the volume, shape, and deformability of a particle in a flow.
[0085] As used herein, the term "homogenization" refers to the process of bringing a biological sample to a state where all fractions of the sample are compositionally equal. In the present disclosure, "homogenization" generally maintains the integrity of most cells within the sample, for example, at least 50, 80, 85, 90, 95, 96, 97, 98, 99, 99.9% or more of the cells in the sample are disrupted or lysed as a result of the homogenization process. The homogenate can be substantially dissociated into individual cells (or cell clusters) and the resulting homogenate is substantially homogeneous (composed or composed of similar elements or uniform throughout).
[0086] As used herein, the term "label" or "dye" refers to an agent capable of binding to an analyte, internalizing or otherwise taking up, and detecting (e.g., via shape, morphology, color, fluorescence, luminescence, phosphorescence, absorbance, magnetism, or radioactive emission).
[0087] As used herein, the term "lymph node" refers to an oval or kidney-shaped organ of the lymphatic system that is widespread throughout the body (including the armpits and stomach) and connected by lymphatic vessels. Lymph nodes contain a variety of immune cells, including but not limited to B cells and T cells. In some embodiments, lymph nodes may contain hidden tumor cells.
[0088] As used herein, the term "microfluidic" means having at least one dimension less than 1 mm.
[0089] As used herein, the term "next generation sequencing (NGS)" refers to sequencing technologies with high throughput sequencing compared to traditional Sanger and capillary electrophoresis-based approaches, in which the sequencing process is performed in parallel, e.g., thousands or millions of relatively small sequence reads are generated at a time. Some examples of next generation sequencing technologies include, but are not limited to, sequencing by synthesis, sequencing by ligation, and sequencing by hybridization. These technologies generate shorter reads (anywhere between 25-500 bp) but generate hundreds of thousands or millions of reads in a relatively short time. The term "next generation sequencing" refers to the so-called parallelized sequencing by synthesis or sequencing by ligation platforms currently used by Illumina, Life Technologies, and Roche, among others. Next generation sequencing methods may also include nanopore sequencing methods or methods based on electronic detection, such as the Ion Torrent technology commercialized by Life Technologies.
[0090] As used herein, the term "normal tissue" refers to tissue that has no detectable damage or abnormality presumed to be associated with an increased incidence of disease or malignancy in the context of cancer. These normal samples can be derived from patients with genetic mutations or conditions associated with an increased incidence of disease (genetic or otherwise), cancer or malignancy. Normal tissue can be tissue of the same type corresponding to pathological tissue from the same individual, or a different individual; or normal tissue that is unrelated to pathological tissue from the same individual or another individual (e.g., from a different location in the body or having a different histological type).
[0091] As used herein, the term "obstruction" refers to an obstacle to flow in a channel (such as a flow channel in a microfluidic device), such as a protrusion from a surface. For example, an obstruction can refer to a post protruding from a base matrix or a hydrophobic barrier to an aqueous fluid. In some embodiments, the obstruction can be partially permeable. For example, the obstruction can be a post made of a porous material, wherein the pores allow the aqueous component to penetrate but are too small for the separated particles to enter.
[0092] As used herein, the terms "representative sample" and "representative sampling" refer to a sample (or a subset of a sample) that accurately reflects the composition of the whole, so that the sample is an unbiased indication of the entire population. Generally speaking, this means that the different types of cells and their relative proportions or percentages within a representative sample or a portion thereof essentially accurately reflect or mimic the relative proportions or percentages of these cell types within the entire tissue specimen (generally a solid tumor or a portion thereof).
[0093] As used herein, "sequencing" or "DNA sequencing" refers to a biochemical method for determining the order of nucleotide bases, adenine, guanine, cytosine, and thymine in a DNA oligonucleotide. As the term is used herein, sequencing may include, but is not limited to, parallel sequencing or any other sequencing method known to those skilled in the art, such as chain termination methods, rapid DNA sequencing methods, wandering spot analysis, Maxam-Gilbert sequencing, dye-terminator sequencing, or use of any other modern automated DNA sequencing instrument.
[0094] As used herein, the term "substantially" means a qualitative condition that exhibits a characteristic or property of interest to a full or near full extent. One skilled in the art will appreciate that biological and chemical phenomena rarely, if ever, complete and / or proceed to completion or achieve or avoid an absolute result. In some embodiments, "substantially" means within about 20%. In some embodiments, "substantially" means within about 15%. In some embodiments, "substantially" means within about 10%. In some embodiments, "substantially" means within about 5%.
[0095] As used herein, the term "tumor" refers to an abnormal new growth or growth of cells that is defined as a mass or growth of cells that usually grows faster than normal cells and, if not treated, will continue to grow, sometimes causing damage to adjacent structures. Tumor size can vary widely. Tumors can be solid or fluid-filled. Tumors can be benign (non-malignant, generally harmless) or malignant (capable of metastasizing) growths. Some tumors may contain benign neoplastic cells (such as carcinoma in situ) and at the same time contain malignant cancer cells (such as adenocarcinoma). This should be understood to include neoplasms located in multiple locations throughout the body. Therefore, for the purposes of this disclosure, tumors include primary tumors, lymph nodes, lymphatic tissue, and metastatic tumors.
[0096] As used herein, the term "tumor sample" encompasses a sample prepared from a tumor or a sample that potentially contains or is suspected of containing cancer cells, or is to be tested for the potential presence of cancer cells, such as a lymph node.
[0097] Self-organization cell granules
[0098] refer to Figure 1 and 2 In some embodiments, cell particles (e.g., cells, nuclei, and / or small tissue aggregates) are separated from a tissue (step 100), such as by homogenizing a tissue sample (step 200), and then dissociating cell particles present in the homogenized sample (step 210). The dissociated cell particles can then be sorted (step 220) and analyzed (step 230).
[0099] In some embodiments, the tissue sample used for homogenization (step 200) and dissociation (step 210) is derived from a tumor (cancerous or non-cancerous), a metastatic lesion, a normal tissue, whole blood, or a lymph node. In some embodiments, the tissue sample is a residual surgical sample, a biopsy sample, or a histological sample. In some embodiments, the tissue sample is a fresh sample, i.e., a sample that has not been preserved. In some embodiments, the tissue sample is a fixed tissue sample. In some embodiments, the tissue sample is derived from a formalin-fixed, paraffin-embedded tissue block. In some embodiments, multiple tissue sources can be combined, and then cell particles, such as cells and / or nuclei, are separated from the collected tissue samples. In some embodiments, cell particles are dissociated from the tissue sample without a homogenization step.
[0100] Specific embodiments for homogenizing and / or dissociating cell particles from tissue are listed herein in the Examples.
[0101] Homogenization of tissue samples
[0102] In some embodiments, a tumor sample, a lymph node sample, and / or other tissue sample is homogenized by placing the sample into a mechanical shearing device, such as a mixer or a sonicator (step 200). The homogenization generates a series of tissue fragments. Methods for preparing a homogenized tumor sample or lymph node sample are disclosed in co-pending PCT Application No. PCT / US2016 / 060861 (filed on November 1, 2016), the disclosure of which is hereby incorporated by reference in its entirety.
[0103] In some embodiments, the homogenized sample is a representative sample as defined herein. Thus, after sufficient mechanical shearing to dissociate the tumor, lymph node, and / or other tissue sample, all tumor cell subpopulations that were initially spatially separated within the original sample are distributed throughout the newly homogenized sample. That is, as a result of homogenizing the tumor, one or more lymph nodes, or any combination thereof, any heterogeneity of cells within the tumor is substantially homogenized (evenly) distributed within the resulting homogenate or its portion or fraction, such that the homogenate (or any fraction thereof) substantially homogenizes the heterogeneity of the input tumor and / or lymph node sample. By homogenizing the tumor and / or lymph node to generate a sample (or homogenate) that is representative of the tumor as a whole, it is possible in some embodiments to characterize the landscape (such as heterogeneity) of the tumor, for example, it may be possible to sequence each of the different cell populations or nuclei contained in the whole (step 230), including different tumor subpopulations, i.e., those with different genomic profiles.
[0104] Dissociation of cells, nuclei, and / or small tissue aggregates from tumors
[0105] The homogenized sample (from step 200) can be further dissociated and / or processed to provide dissociated cell particles (such as dissociated cells or nuclei) and / or small tissue aggregates (step 210). Generally speaking, there are three main methods to dissociate tissue, including enzymatic dissociation, chemical dissociation, and mechanical dissociation or any combination thereof. The choice of dissociation method is usually based on the tissue type and tissue origin.
[0106] Enzymatic dissociation is the process of using enzymes to digest tissue fragments, thereby releasing cells from the tissue. Many different types of enzymes can be used in this process, and as the technician will appreciate, certain enzymes are more effective for certain tissue types. The technician will also appreciate that any enzymatic dissociation process can use one or more enzymes combined with each other, or one or more enzymes combined with other chemical and / or mechanical dissociation methods. Examples of suitable enzymes include, but are not limited to, collagenase, trypsin, elastase, hyaluronidase, papain, DNase I, neutral protease, and trypsin inhibitor.
[0107] Collagenase is a proteolytic enzyme used to digest proteins found in the extracellular matrix. Unique to proteases, collagenase attacks and degrades triple-helical native collagen fibrils commonly found in connective tissues. There are four basic types of collagenase, namely: type 1, which is suitable for use in epithelial, liver, lung, adipose and adrenal tissue cell specimens; type 2, which is suitable for use in heart, bone, muscle, thyroid and cartilage tumor origin tissues due to its high proteolytic activity; type 3, which is suitable for use in breast cells due to its low proteolytic activity; and type 4, which is suitable for pancreatic islets and other research protocols where receptor integrity is important due to its pancreatic activity.
[0108] Trypsin is described as a pancreatic serine (an amino acid) protease with specificity for peptide bonds involving the carboxyl groups of arginine and lysine amino acids. It is considered one of the most specific proteases. Trypsin alone is generally ineffective for tissue dissociation because it shows minimal selectivity for extracellular proteins. It is often combined with other enzymes, such as collagenase or elastase.
[0109] Elastase is another pancreatic serine protease that is specific for peptide bonds next to neutral amino acids. Its ability to hydrolyze native elastin is unique among proteases. Elastase can also be found in blood components and bacteria. In some embodiments, it is suitable for isolating type II cells from lung tissue.
[0110] Hyaluronidase is a polysaccharidase that is often used to dissociate tissue, typically in combination with a more crude protease, such as collagenase. It has an affinity for the bonds found in almost all connective tissues.
[0111] Papain is a sulfhydryl protease that has broad specificity and is therefore able to degrade most protein substrates more thoroughly than the pancreatic proteases, trypsin or elastase. Papain is frequently used to self-isolate neuronal material.
[0112] Deoxyribonuclease I (DNase I) is frequently included in enzymatic cell separation procedures to digest nucleic acids that leak into the dissociation medium and can increase stickiness and recovery problems. Without wishing to be bound by any particular theory, it is believed that DNase I does not destroy intact cells.
[0113] Neutral proteases, such as (available from Worthington Biochemical), is a bacterial enzyme with mild proteolytic activity that is used to maintain cell membrane integrity. Useful for dissociating primary and secondary cell cultures. It was found to be more effective in dissociating fibroblast-like cells than epithelial-like cells. It is inhibited by EDTA.
[0114] Trypsin inhibitors, derived primarily from soybeans, inactivate trypsin and are therefore sometimes used in certain cell isolation protocols.
[0115] Chemical dissociation takes advantage of the fact that cations are involved in the maintenance of intracellular bonds and the intracellular matrix. By introducing EDTA or EGTA, which bind to these cations, the intercellular bonds are disrupted, thereby allowing the dissociation of tissue structures.
[0116] Finally, mechanical dissociation requires cutting, scraping or rubbing the tissue into small pieces, then washing the minced tissue in culture medium to separate cells from the tissue, and sometimes using gentle shaking to help loosen the cells. In other embodiments, mechanical dissociation may involve homogenizing the sample, as further described herein.
[0117] In some embodiments, cells in a homogenized sample, or a homogenized and filtered sample, are lysed to release cellular components. For example, cells can be lysed using a French crusher or similar type of lysis instrument, a microfluidizer, grinding, milling, chemical or enzymatic lysis (including those described above), and / or other techniques known in the art. In some embodiments, membrane lipids and proteins (including histones) are removed from a sample containing cellular components (e.g., by adding a surfactant or enzyme (protease)).
[0118] Further processing of the homogenized, representative, or dissociated sample into individual nuclei requires removal of the cell membrane. Current nuclear isolation methods for fresh cells do not require enzymes to release the nuclei, and isolating nuclei from formalin-fixed samples is not a common method. In order to effectively isolate individual nuclei while maintaining cytoskeletal markers that can distinguish normal and tumor nuclei, enzymes (e.g., pronase, proteinase K, pepsin, trypsin, Accumax, collagenase H) can be used to remove the nuclei without excessive damage that would release DNA from the treated nuclei. Specific methods for isolating nuclei from homogenates or representative samples are disclosed in co-pending PCT Application No. PCT / US2016 / 060861, the disclosure of which is hereby incorporated herein by reference in its entirety.
[0119] Sorting of isolated cell pellets
[0120] After separating cell particles (such as cells or nuclei) and / or small tissue aggregates from a tissue sample (step 100) or more specifically, homogenizing (step 200) and dissociating (step 210) the cell particles and / or small tissue aggregates, the cell particles and / or small tissue aggregates are sorted (step 110 or 220). In some embodiments, sorting of the separated cell particles and / or small tissue aggregates occurs without staining the cell particles and / or small tissue aggregates.
[0121] In some embodiments, cell particles and / or small tissue aggregates are sorted into two or more populations based on their size. In some embodiments, cell particles and / or small tissue aggregates are sorted based on their hydrodynamic size. For example, it is believed that tumor cells, nuclei, and / or tumor tissue aggregates are generally larger in size than normal cells, normal nuclei, and normal tissue aggregates, respectively. Therefore, it is believed that a sorting device can be used to reproducibly distribute a heterogeneous sample containing both tumor cells or nuclei and normal cells or nuclei into at least two discrete unit populations (step 220), followed by downstream processing or analysis (step 230).
[0122] Applicants have found that dissociated, fixed tumor tissue reproducibly distributes particles with two different size distributions (see Examples herein). In fact, after staining samples for fluorescent tumor markers and FACS sorting "tumor" and "normal" populations, Applicants found significant and reproducible size differences between tumor and normal material (both cells and nuclei). Applicants showed that cell particles in the smaller fractions were negative for tumor markers and contained diploid DNA, while cell particles in the larger fractions were positive for tumor markers and had higher DNA content, indicating cycling or aneuploid cells (confirming that they are likely tumor cells) (see Examples herein).
[0123] In some embodiments, normal cells are considered to have a size ranging from about 4 μm to about 12 μm, depending of course on the type of cell or tissue from which the cell originates, and whether the tissue from which the cell originates is preserved, such as formalin fixed, paraffin embedded. In some embodiments, normal cells isolated from formalin fixed tissues have a size ranging from about 5 μm to about 12 μm. In still other embodiments, normal cells from fixed tissues have a size less than 12 μm.
[0124] In some embodiments, it is believed that tumor cells have a size ranging from about 9 μm to about 100 μm, depending of course on the type of cell or tissue from which the cell originates, and whether the tissue from which the cell originates is preserved, such as formalin fixed, paraffin embedded. In some embodiments, tumor cells isolated from fixed tissues have a size ranging from about 9 μm to about 20 μm. In other embodiments, tumor cells isolated from fixed tissues have a size ranging from about 9 μm to about 50 μm. In other embodiments, tumors isolated from fixed tissue cells have a size ranging from about 12 μm to about 25 μm. In still other embodiments, tumor cells isolated from fixed tissues have a size greater than 12 μm.
[0125] In some embodiments, tumor cells may have an average size that is at least about 30% larger than corresponding normal cells. In other embodiments, tumor cells may have an average size that is at least about 35% larger than corresponding normal cells. In still other embodiments, tumor cells may have an average size that is at least about 40% larger than corresponding normal cells. In other embodiments, tumor cells may have an average size that is at least about 45% larger than corresponding normal cells. In still other embodiments, tumor cells may have an average size that is at least about 50% larger than corresponding normal cells. In even other embodiments, tumor cells may have an average size that is at least about 55% larger than corresponding normal cells. In even other embodiments, tumor cells may have an average size that is at least about 70% larger than corresponding normal cells. In even other embodiments, tumor cells may have an average size that is at least about 90% larger than corresponding normal cells. In even other embodiments, tumor cells may have an average size that is at least about 100% larger than corresponding normal cells.
[0126] It is believed that tumor and normal cells isolated from fresh solid tumor tissue will have different relative sizes similar to fixed tissue. Freshly dissociated tissue refers to tissue removed from the body and processed into single cells within a predetermined time period, such as within 24 hours, within 18 hours, within 12 hours, or within 6 hours, without being placed in formalin and before any fixation process, resulting in mainly intact, viable cells. After dissociation, cells derived from fresh tissue can be cultured or briefly fixed (typically in about 3% paraformaldehyde) before analysis. Dissociation of fresh tissue can be achieved using a variety of previously described protocols or commercially available kits, typically involving both mechanical and enzymatic steps (such as disclosed herein).
[0127] In some embodiments, it is believed that normal nuclei isolated from fixed tissues have a size ranging from about 4.5 μm to about 9 μm, depending of course on the type of tissue from which the cell or nucleus originates, and whether the tissue from which the nucleus originates is preserved, such as formalin-fixed, paraffin-embedded. In other embodiments, normal nuclei have a size ranging from about 5 μm to about 8.5 μm. In still other embodiments, normal cells have a size less than 8.5 μm. It is expected that normal nuclei isolated from fresh tissues may have a size range similar to or slightly larger than those isolated from fixed tissues.
[0128] Tumor nuclei isolated from fixed tissue are believed to have a size ranging from about 7.5 μm to about 20 μm, depending of course on the type of tissue from which the cell or nucleus originates, and whether the tissue from which the nucleus originates is preserved, e.g., formalin-fixed, paraffin-embedded. In other embodiments, tumor nuclei have a size ranging from about 8.5 μm to about 20 μm. In other embodiments, tumor nuclei have a size ranging from about 9 μm to about 18 μm. In other embodiments, tumor nuclei have a size ranging from about 9.5 μm to about 15 μm. In still other embodiments, tumor cells have a size greater than about 8.5 μm.
[0129] In some embodiments, dissociation can produce monomeric normal cells (e.g., immune cells) that are more easily dissociated and generate tumor cell aggregates that are less easily dissociated. In some embodiments, tumor cell aggregates can be distinguished from monomeric normal cells by size. In some embodiments, the size range of dissociated fixed normal cells is about 4 to about 8.5 μm. Tumor cell aggregates can be composed of about 2 to more than 100 cells, depending on the characteristics of the tissue and the dissociation method used. Tumor cell aggregates can be composed of groups of cells larger than about 20 μm, about 50 μm, about 100 μm, about 300 μm, or about 500 μm.
[0130] In some embodiments, cell particles (e.g., cells or cell nuclei) having a first size range are sorted into a first population, and cell particles (e.g., cells or cell nuclei) having a second size range are sorted into a second population, wherein the first population contains at most 30% of cell particles having the second size range. In some embodiments, the first population contains at most 25% of cell particles having the second size range. In some embodiments, the first population contains at most 20% of cell particles having the second size range. In some embodiments, the first population contains at most 15% of cell particles having the second size range. In some embodiments, the first population contains at most 10% of cell particles having the second size range. In some embodiments, the first population contains at most 7.5% of cell particles having the second size range. In some embodiments, the first population contains at most 5% of cell particles having the second size range. In some embodiments, the first population contains at most 2.5% of cell particles having the second size range. In some embodiments, the first population contains at most 1% of cell particles having the second size range.
[0131] Sorting device
[0132] In some embodiments, the sorting device is an instrument or apparatus that directs cells or nuclei having a first size in a first direction and cells or nuclei having a second size in a second direction without first staining the cells or nuclei or labeling them with any agent (e.g., magnetic particles, etc.).
[0133] In some embodiments, the sorting device is a microfluidic device. Microfluidics is a technology that can achieve the sorting of cells and / or nuclei according to size. Thus, in some embodiments, microfluidic-based technology is used to achieve sorting. In some embodiments, microfluidic devices, such as disposable microfluidic devices, are used to achieve sorting. Non-limiting examples of microfluidic technology are described herein. Additional examples of microfluidic techniques that can be performed as part of the present method are disclosed in the following references, each of which is incorporated herein by reference in its entirety: (i) C. Wyatt Shields IV, Dr. Catherine D. Reyes, and Prof. Gabriel P. López, Microfluidic Cell Sorting: A Review of the Advances in the Separation of Cells from Debulking to Rare Cell Isolation, Lab Chip. 2015 February 16; 15(5): 1230-1249; and (ii) P. Sajeesh and Ashis Kumar Sen, Particle Separation and Sorting in Microfluidic Devices: A Review, Microfluid Nanofluid (2014) 17: 1-52.
[0134] In some embodiments, the sorting device is a device that employs an array of a network of gaps, wherein a fluid flowing through a gap is unequally divided into subsequent gaps. "Gap" means an opening through which a fluid or particle can flow. For example, a gap can be a space between two obstacles in which a fluid can flow, or a hydrophilic pattern on a hydrophobic surface elsewhere where an aqueous fluid is restricted. The array includes a network of gaps arranged so that the fluid flowing through the gaps is unequally divided, although the dimensions of the gaps may be the same. In some embodiments, the method utilizes a flow carrying cells to be separated via an array of gaps. In some embodiments, the flow is aligned at a small angle (flow angle) with respect to the line of sight of the array. In some embodiments, cells or nuclei having a hydrodynamic size larger than the critical size migrate through the array along the line of sight, i.e., laterally, while those having a hydrodynamic size smaller than the critical size follow the average flow direction. Without wishing to be bound by any particular theory, it is believed that the flow in the device occurs under laminar flow conditions. The device of the present disclosure is optionally configured as a continuous flow device. In some embodiments, the critical size is at least 8.5 μm. In other embodiments, the critical size is at least 9 μm. In still other embodiments, the critical dimension is at least 10 μm. In other embodiments, the critical dimension is at least 12 μm. Of course, the skilled artisan will appreciate that the critical dimension can be modified to accommodate different types of cells, cells from different origins, and fresh versus fixed cells. The skilled artisan will also appreciate that the critical dimension can be increased or decreased to improve the purity or yield of the collected population.
[0135] In some embodiments, separation of cells by a sorting device can be based on at least one differential rolling characteristic of a target cell compared to a non-target cell. In certain embodiments, target cells are cells that share a common characteristic that is recognized by a cell adhesion entity coated on a three-dimensional structure. Generally speaking, target cells turn away from the direction of the general flow by cell rolling, while non-target cells that are not recognized by the cell adhesion entity do not roll and do not turn away from the direction of the general flow. Although the present disclosure generally refers to cells that turn as "target cells", it will be appreciated that this is an arbitrary designation, and in certain embodiments, separation of cells can be performed in a negative selection mode, whereby the true "target cells" are in fact cells that do not turn.
[0136] The skilled artisan will appreciate that multiple sorting devices can be used in series, for example, cells can be passed through a first and a second device that both employ deterministic lateral displacement, or cells can be passed through a first device that utilizes deterministic lateral displacement and a second device that employs a different microfluidic technology. In some embodiments, the first sorting device sorts the input material into first and second populations, while the second sorting device refines the sorting, for example, sorting the first population into first and second subpopulations. In some embodiments, the sorting device can be coupled to a second enrichment technique that optionally requires staining or labeling of the separated cells or nuclei (e.g., flow cytometry, magnetic separation).
[0137] Deterministic lateral displacement
[0138] Deterministic Lateral Displacement (DLD) is a three-dimensional method for continuous separation that exploits the asymmetric bifurcation of laminar flow around an obstacle (see Fig.11 ). For example, particles (here cells or nuclei) moving through an array of obstacles with gaps larger than the particle size choose their path deterministically based on their size and deformability. Particles of given size and deformability are considered to follow equivalent migration paths, resulting in an efficient separation method.
[0139] In general, the critical diameter for separation is described by Dc=2ηdε, where η is a unitless parameter, d is the distance between the edges of adjacent obstacles and ε is the row displacement fraction (see, e.g., Huang et al., Science 2004, 304(5673):987-990). E is defined as ε=Δd / W, where W is the center-to-center distance of two adjacent obstacles in the same row and Δd is the lateral displacement between two adjacent obstacles in consecutive rows. Particles larger than Dc, such as cells, are forced to move at an angle relative to the direction of the bulk flow by repeated collisions with obstacles. Repeated collisions can be advantageously used in the context of the present disclosure to promote interactions between cells and obstacle surfaces coated with cell adhesion entities.
[0140] The obstructions in the array typically protrude from the inner surface (e.g., lower surface, upper surface, sidewall, or combination thereof) of the sorting channel. In certain embodiments, the protrusion spans the distance between the lower and upper surfaces of the sorting channel. The obstructions may have any shape, such as, but not limited to, square, rectangular, triangular, trapezoidal, hexagonal, teardrop, polygonal, elliptical, circular, arc-shaped, wavy, and / or combinations thereof.
[0141] In some embodiments, the device is designed for use with cells having an average diameter D and the critical diameter Dc is designed to be less than D. In some embodiments, the sorting channel may have a critical diameter Dc of less than about 7 μm, about 7.5 μm, about 8 μm, about 8.5 μm, about 9 μm, about 10 μm, or less than about 12 μm. In some embodiments, the sorting channel may have a critical diameter Dc greater than about 7 μm, about 7.5 μm, about 8 μm, about 8.5 μm, about 9 μm, about 10 μm, or greater than about 12 μm. In certain embodiments, the sorting channel may have a critical diameter Dc in a range between any two of these values. For example, in certain embodiments, the sorting channel may have a critical diameter Dc in a range of about 6 μm to about 8.5 μm, such as about 7 μm to about 9 μm, about 9 μm to about 12 μm, etc. One skilled in the art will appreciate that the critical diameter may be increased or decreased to improve the purity or yield of the collected population.
[0142] Fluid Dynamics Focus
[0143] In some embodiments, the sorting channel uses hydrodynamic focusing to separate cells. Generally, a sorting channel that relies on hydrodynamic focusing will include a contraction region and an expansion region. Hydrodynamic focusing works by forcing cells to line up in a single file along the longitudinal direction (by covering the sample flow with a sheath flow). In certain embodiments of the present disclosure, the position of the cell in the expansion region (in the absence of cell rolling) can be determined by Wp={W2 / W1)d, where d is the diameter of the cell, W1 is the width of the contraction region and W2 is the width of the expansion region. Typically, the sheath flow forces the cell to contact the sidewalls of the contraction region, and in the context of the present disclosure, this can be used to promote the interaction between the cell and the sidewall surface coated with a cell adhesion entity. As shown in Figure 13, the presence of the coating can cause cells that would otherwise arrive at the expansion region at position Wp to roll along the sidewalls of the expansion region and leave at different positions in the expansion region. It will be appreciated that the specific dimensions of W1 and W2 and the flow rates of the sheath and sample flows can be adjusted according to the properties of the sorted cells and the properties of the coating.
[0144] Acoustophoresis
[0145] Label-free acoustofluidic systems generally sort cells based on differences in their size. This cell sorting method relies on initially placing cells in the flow line away from a pressure node so that they quickly move to the node when the device is activated, thereby separating cells with different sizes or acoustic properties.
[0146] In some embodiments, fluid dynamics are used to direct cells or nuclei to the side walls of the acoustic fluidic device, whereupon they migrate toward the nodes of the acoustic standing wave at a rate proportional to their volume. It is believed that larger cells experience larger forces in the acoustic standing wave, thus responding faster to the radiative forces, thus directing larger cells to the central outlet (e.g., the node) and smaller cells to the side outlets. Acoustophoresis methods are further described in at least (i) Petersson F, Nilsson A, Holm C, Jonsson H, Laurell T. The Analyst. 2004; 129: 938-943 [PubMed: 15457327]; (ii) Petersson F, Nilsson A, Holm C, Jonsson H, Laurell T. Lab Chip. 2005; 5: 20-22 [PubMed: 15616735]; (iii) Petersson F, Aberg L, Sward-Nilsson AM, Laurell T. Analytical Chemistry. 2007; 79: 5117-5123 [PubMed: 17569501]; (iv) Dykes J, Lenshof A, Astraand-Grundstrom I, Laurell T, Scheding S. PloS one.2011;6:e23074[PubMed:21857996]; (v) Augustsson P, Magnusson C, Nordin M, Lilja H, Laurell T. Anal. Chem. 2012;84:7954-7962[PubMed:22897670]; (vi) Yang AH, Soh HT. Analytical chemistry. 2012;84:10756-10762[PubMed:23157478]; and (vii) Fong EJ, Johnston AC, Notton T, Jung SY, Rose KA, Weinberger LS, Shusteff M. The Analyst. 2014;139:1192-1200[PubMed:24448925], the disclosures of which are hereby incorporated herein by reference in their entirety.
[0147] Inertial focusing in curved channels
[0148] Inertial forces can result in induced migration of cells or particles across streamlines in laminar flow. Typically, inertial forces arise from boundary effects of fluid flow adjacent to the walls of microfluidic channels, causing lift. Inertial focusing in curved channels refers to a unique subset of phenomenological techniques for cell fractionation, which includes cell sorting and separation using serpentine or Archimedean spiral patterns.
[0149] Apparatus and techniques for performing inertial focusing in curved channels are further described in at least the following references, the disclosures of which are hereby incorporated by reference in their entirety herein: (i) Di Carlo D, Edd JF, Irimia D, Tompkins RG, Toner M. Analytical Chemistry. 2008;80:2204-2211 [PubMed:18275222]; (ii) Oakey J, Applegate RW Jr, Arellano E, Di Carlo D, Graves SW, Toner M. Analytical chemistry. 2010;82:3862-3867 [PubMed:20373755]; (iii) Russom A, Gupta AK, Nagrath S, Di Carlo D, Edd JF, Toner M. New J Phys. 2009;11:75025; (iv) Kuntaegowdanahalli SS, Bhagat AA,Kumar G,Papautsky I.Lab Chip.2009;9:2973-2980[PubMed:19789752];(v)Hou HW,Warkiani ME,Khoo BL,Li ZR,Soo RA,Tan DS-W,Lim WT,Han J,Bhagat AAS,Lim CT.Scientific Reports.2013;3:1-8; (vi) Nivedita N, Papautsky I. Biomicrofluidics.2013;7:54101[PubMed:24404064]; and (v)Guan G, Wu L, Bhagat AA, Li Z, Chen PC, Chao S, Ong CJ, Han J.Sci Rep. 2013;3:1475 [PubMed:23502529].
[0150] Narrow Flow and Hydrodynamic Diffusion
[0151] In addition to curved channels (documented above), inertial forces can also play a crucial role in straight channels. Pinching and hydrodynamic diffusion are two examples of inertial forces that play a role in ordering cells for subsequent sorting. Pinching occurs when the flow stream of cells is squeezed by a narrow channel cross section, causing the cells to become constrained and aligned against the side walls, and then separated by size due to laminar flow profiles once the channel widens (see Fig.10 ). This alignment effect is typically enhanced by a sheath fluid that pushes the cells toward the wall, causing the centers of larger cells to be farther from the wall surface than the centers of smaller cells, thus imparting slightly different flow trajectories to cells of different sizes as the channel widens. This sorting approach has been extended by adding multiple asymmetric outlets for better fluid dynamic control and by spatial reorientation of the microfluidic device to achieve gravity-enhanced separation between cell populations of different sizes and masses.
[0152] Apparatus and techniques for performing pinch flow and hydrodynamic diffusion are further described in at least the following references, the disclosures of which are hereby incorporated by reference in their entirety: (i) Di Carlo D. Lab Chip. 2009; 9:3038-3046 [PubMed: 19823716]; (ii) Di Carlo D, Irimia D, Tompkins RG, Toner M. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:18892-18897 [PubMed: 18025477]; (iii) Di Carlo D, Edd JF, Irimia D, Tompkins RG, Toner M. Analytical Chemistry. 2008; 80:2204-2211 [PubMed: 18275222]; (iv) Oakey J, Applegate RW Jr, Arellano E, Di Carlo D, Graves SW, Toner M. Analyticalchemistry. 2010; 82:3862-3867 [PubMed: 20373755]; (v) Russom A, Gupta AK, Nagrath S, Di Carlo D, Edd JF, Toner M. New J Phys. 2009; 11:75025; (vi) Kuntaegowdanahalli SS,Bhagat AA,Kumar G,Papautsky I.Lab Chip.2009;9:2973-2980[PubMed:19789752];(vii)Hou HW,Warkiani ME,Khoo BL,Li ZR,Soo RA,Tan DS-W,Lim WT,Han J,BhagatAAS,Lim CT.Scientific Reports.2013;3:1-8;(viii)Nivedita N,PapautskyI.Biomicrofluidics.2013;7:54101.[PubMed:24404064];(ix)Guan G,Wu L,Bhagat AA,Li Z,Chen PC,Chao S,Ong CJ,Han J.Sci Rep.2013:3:1475[PubMed:23502529]N(x)Warkiani ME,Guan G,Luan KB,Lee WC,Bhagat AA,Chaudhuri PK,Tan DS,Lim WT,LeeSC,Chen PC,Lim CT,Han J.Lab Chip.2014:14:128–137[PubMed:23949794];(xi)Parichehreh V,Medepallai K,Babbarwal K,Sethu P.Lab Chip M,Nakashima M,Seki M.AnalyticalChemistry.2004:76:5465–5471[PubMed:15362908].
[0153] Hydrophoretic Filtration
[0154] Ridge-induced hydrophoretic filtration relies on the formation of lateral pressure gradients within microfluidic channels caused by changing the micropattern of flow. Continuous arrays of inclined obstacles on the bottom and top surfaces of the microchannel induce pressure gradients across the width of the channel, thereby focusing cells by type to precise locations within the generated local pressure field and then separating those cells. Apparatus and techniques for hydrophoretic filtration are further described in at least the following references, the disclosures of which are hereby incorporated by reference in their entirety: (i) Choi S, Song S, Choi C, Park JK. Lab Chip. 2007;7:1532-1538 [PubMed:17960282]; (ii) Hsu CH, Di Carlo D, Chen C, Irimia D, Toner M. Lab Chip. 2008;8:2128-2134 [PubMed:19023476]; (iii) Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP Jr, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee JB, et al., 2008;9:114-115 [PubMed:114-115 [PubMed:114-115 RJ,Isselbacher KJ,Maheswaran S,Haber DA,Toner M.Proceedings of the National Academy of Sciences of the United States of America.2010;107:18392-18397[PubMed:20930119];(iv)Sollier E,Go DE,Che J,Gossett DR,O'Byrne S,Weaver WM,Kummer N, Rettig M, Goldman J, Nickols N, McCloskey S, Kulkarni RP, Di Carlo D. Lab Chip. 2014; 14:63-77 [PubMed:24061411]; and (v) Hyun KA, Kwon K, Han H, Kim SI, Jung HI. Biosensors&bioelectronics. 2013;40:206-212 [PubMed:22857995].
[0155] Size Exclusion Filtration
[0156] Instead of designing the size and pattern of uniformly spaced posts to sort cells, size exclusion filtration refers to the use of posts with tiered (i.e., increasingly smaller) spacing as a function of distance to sort cells in a non-binary manner. Size exclusion filters consist of a series of linear arrays of posts that selectively group cells by size and shape.
[0157] Cross flow filtration
[0158] Filtration of fluids containing cells was one of the earliest methods used to fractionate cell populations. Examples of these filters include weir filters containing large barriers to capture large cells, column filters containing an array of microscopic pillars of equal size to capture large cells, and membrane filters containing an array of holes on the bottom or top surface to capture large cells.
[0159] Cross-flow filtration, sometimes called tangential flow filtration, uses an array of lateral slits aligned in the direction of flow to fractionate cell populations by size. Without wishing to be bound by any particular theory, it is believed that this filtration method is a significant improvement over earlier types of filters, such as weirs, columns, and membranes, because they are less likely to clog because they behave more like a sieve than dead-end filters.
[0160] Fluid Dynamic Filtration
[0161] In hydrodynamic filtration, cells are separated by multiple branching outlets, whereby the fluid exiting the outlets pulls the cells away from the walls of the main channel at a rate proportional to their size (see Fig.12 ). Smaller cells exit the proximal outlet because their centers are closer to the walls of the microfluidic channel, allowing for controlled diversion of them from larger cells.
[0162] like Fig.13A As shown in , a sorting channel that relies on hydrodynamic filtration can contain a main channel and multiple side channels. Fig. 13B As shown in , at the branch between the main and side channels, the flow rate ratio determines whether the cell (or nucleus) continues to flow through the main channel or enters the side channel to leave. Generally, in the absence of cell rolling, cells larger than a certain width are forced to flow through the main channel rather than the side channel by repeatedly aligning against the side wall. In the context of the present disclosure, such repeated alignment can be used to promote interaction between cells and channel wall surfaces coated with cell adhesion entities. Advantageously, cells (or nuclei) that would normally continue to travel along the main channel can be caused to enter the side channel and roll, such as Fig.13A In certain embodiments, the side walls of the main channel are therefore coated with a cell adhesion entity so that target cells can be bound and rolled on the side walls.
[0163] Vortex Sorting Device
[0164] In some embodiments, the sorting device is a Vortex HE device, available from Vortex Biosciences. In some embodiments, the Vortex HE device is a microfluidic device that uses a high aspect ratio microfluidic channel for particle focusing followed by multiple expansion regions (see Fig.14 Without wishing to be bound by any particular theory, it is believed that particles (or cells) enter the expansion region behind the narrow focusing channel due to shear gradient lift. The lift is a balance between the wall lift that pushes the particles away from the wall and the lateral shear gradient lift determined by the fluid velocity profile around the particle. Small particles (or cells) do not experience sufficient shear gradient lift and focus toward the middle of the channel and do not enter the expansion region. Increasing lift by reducing the cross-sectional area of the upstream focusing channel allows smaller particles (or cells) to migrate across the mainstream and into the expansion region (e.g., cells trapped in the expansion region). The Vortex HE device is further described in PCT / US2016 / 038230, the disclosure of which is hereby incorporated by reference in its entirety. The Vortex separation method is also disclosed in Manjima Dhar et al., "High Efficiency Vortex Trapping of Circulating Tumor Cells," Biomicrofluidics 9, 064116 (2015), the disclosure of which is hereby incorporated by reference in its entirety.
[0165] Other sorting devices
[0166] The separated samples may also be sorted by other devices or instruments, including conventional filtration (eg, using a cell strainer or sieve); tangential filtration; column-based filtration; and centrifugation (density gradient centrifugation).
[0167] Microfluidic device fabrication
[0168] In general, any material used as a microfluidic device can be patterned in practice using lithography or other techniques known to those skilled in the art. Exemplary methods for preparing suitable devices are disclosed in U.S. Pat. No. 6,197,575, U.S. Pat. Publication No. 2010 / 0112026, and U.S. Pat. Publication No. 2010 / 0304485, the entire contents of which are incorporated herein by reference. In various embodiments, the microfluidic device can be made in whole or in part from poly (dimethylsiloxane) (PDMS), glass, silica, or fluoropolymers. In certain embodiments, the walls of the channel can be treated with materials to change hydrophilicity, protein affinity, cell affinity, or any combination of these. Exemplary treatment materials include, but are not limited to, polyethylene glycol (e.g., poly (3-trimethoxysilyl)-methacrylate-r-poly (ethylene glycol) methyl ether or TMSMA-r-PEGMA), organosilanes that form self-assembled monolayers, ethanol, etc.
[0169] Further analysis
[0170] In some embodiments, the sorted or enriched cell populations, nuclei, and / or small tissue aggregates are further analyzed (steps 120, 230, 330, 430, and 440). In some embodiments, the sorting device can be in fluid communication with a detector, a microscope, a cell counter (e.g., a Coulter counter), a mass spectrometer, a FACS, a PCR device, a RT-PCR device, a genome sequencer, an imaging system, etc. Alternatively, and in other embodiments, the sorting device can provide several cell populations, nuclei, or small tissue aggregates that are retained for later analysis.
[0171] Sequencing
[0172] In some embodiments, at least one of the sorted cells or nuclei populations (step 320 or 420) is sequenced (step 330 or 440). Methods for preparing cells and / or sorted nuclei for sequencing are disclosed, for example, in PCT / US2016 / 060835, the disclosure of which is hereby incorporated herein by reference in its entirety.
[0173] Sequencing (step 330 or 440) can be performed according to any method known to those of ordinary skill in the art. In some embodiments, sequencing methods include Sanger sequencing and dye-terminator sequencing, as well as next-generation sequencing technologies, such as pyrophosphate sequencing, nanopore sequencing, micropore-based sequencing, nanoball sequencing, MPSS, SOLiD, Illumina, IonTorrent, Starlite, SMRT, tSMS, sequencing by synthesis, sequencing by ligation, mass spectrometry sequencing, polymerase sequencing, RNA polymerase (RNAP) sequencing, microscopy-based sequencing, microfluidic Sanger sequencing, microscopy-based sequencing, RNAP sequencing, tunnel current DNA sequencing, and in vitro viral sequencing. See WO2014144478, WO2015058093, WO2014106076 and WO2013068528, each of which is hereby incorporated by reference in its entirety.
[0174] In some embodiments, sequencing (step 330 or 440) can be implemented by a variety of different methods, such as by using sequencing by synthesis technology. According to the prior art, sequencing by synthesis is defined as any sequencing method that monitors the generation of byproducts when a specific deoxynucleoside triphosphate is incorporated during the sequencing reaction (Hyman, 1988, Anal. Biochem. 174: 423-436; Rhonaghi et al., 1998, Science 281: 363-365). A prominent embodiment of sequencing by synthesis reaction is the pyrophosphate sequencing method. In this case, the generation of pyrophosphate during nucleotide incorporation is monitored by an enzymatic cascade that results in the generation of a chemiluminescent signal. The 454 Genome Sequencer System (Roche Applied Science Catalog No. 04 760 085 001), an example of sequencing by synthesis, is based on pyrophosphate sequencing technology. For sequencing on the 454GS20 or 454FLX instruments, the average genomic DNA fragment size is in the range of 200 or 600 bp, respectively, as described in the product literature.
[0175] In some embodiments, sequencing by synthesis reactions may alternatively be based on terminator dye-type sequencing reactions. In this case, the incorporated dye deoxynucleoside triphosphate (ddNTP) building blocks contain a detectable label, which is preferably a fluorescent label that prevents further extension of the nascent DNA chain. The label is then removed and detected when the ddNTP building blocks are incorporated into the template / primer extension hybrid (e.g., by using a DNA polymerase containing a 3′-5′ exonuclease or proofreading activity).
[0176] In some embodiments, and in the case of the genome sequencer workflow (Roche Applied Science catalog number 04 896 548 001), in the first step, (clonal) amplification is performed by emulsion PCR. Thus, it is also within the scope of the present disclosure to perform the amplification step by an emulsion PCR method. The beads carrying the clonally amplified target nucleic acid can then become randomly transferred into a pico titer plate according to the manufacturer's protocol and submitted to a pyrophosphate sequencing reaction for sequence determination.
[0177] In some embodiments, sequencing is performed using a next generation sequencing method, such as that provided by Illumina, Inc. ("Illumina sequencing method"). Without wishing to be bound by any particular theory, Illumina next generation sequencing technology uses clonal amplification and sequencing by synthesis (SBS) chemistry to enable rapid, accurate sequencing. This process simultaneously identifies DNA bases as they are incorporated into a nucleic acid chain. Each base emits a unique fluorescent signal as it is added to the growing chain, which is used to determine the order of the DNA sequence.
[0178] In some embodiments, sequencing is performed using single molecule real-time sequencing, such as PacBio available from Pacific Biosciences of California, Inc.
[0179] In some embodiments, the sorted cells are stained and / or labeled for specific biomarkers. For example, one or both of the two cell populations can be stained and / or labeled for the presence of specific surface markers.
[0180] Flow cytometry
[0181] In some embodiments, flow cytometry analysis (step 430) is performed after sorting the dissociated cells (step 420). Figure 4). Flow cytometry is a technique that allows simultaneous multi-parameter analysis of the physical and / or chemical characteristics of single cells flowing through an optical / electronic detection device. Flow cytometry and its uses are well known to those skilled in the art (see, e.g., Ormerod, Flow Cytometry 2nd ed., Springer-Verlag, New York (1999), incorporated herein by reference). Such uses include, but are not limited to, immunofluorescent labeling of cell surface antigens using monoclonal antibodies. Clinical applications include, but are not limited to, immunophenotyping of leukemias and lymphomas, detection of minimal residual disease, stem cell enumeration, solid organ transplantation including T cell cross-matching and post-operative monitoring, detection of autoantibodies, HIV infection, fetal-maternal bleeding, immunodeficiency disorders, paroxysmal nocturnal hemoglobinuria, reticulocyte analysis, cell cycle analysis, cell proliferation, apoptosis, RNA content, protein content, dynamic analysis of intracellular enzymes, membrane permeability, membrane potential, generation of intracellular oxidative species, measurement of drug uptake, ligand binding and endocytosis, intracellular calcium, intracellular pH, intracellular glutathione, chromosome analysis and sorting, tracking cells, measuring cell viability, monitoring electrical permeability, monitoring cell fusion or clustering, microbead technology, etc.
[0182] Applicants have found that flow cytometry analysis of dissociated tumor samples is challenging because there are multiple cells with different physical characteristics in tumors. Certain routine procedures such as doublet identification rely on having cell populations with fairly homogenous characteristics; for example, in a mixed population, doublets of normal cells may be difficult to distinguish from tumor cells. Size-based fractionation of dissociated samples will simplify flow cytometric analysis by providing two cell populations—one enriched for tumor and one enriched for normal cells—each of which will be easier to stain and analyze individually. After size-based enrichment, staining and FACS will allow technicians to easily sort immune populations that are positive for a particular marker or tumor populations that are positive for a particular marker, and analyze the genomics or proteomics of that particular population. It will also allow the determination of the percentage of tumor cells or immune cells that are positive for a particular marker, even if the technician does not care to collect and further analyze that population.
[0183] Biomarker analysis
[0184] In some embodiments, a population of enriched cells, nuclei, or small tissue aggregates is stained in an assay to identify a specific target molecule. The target molecule can be a nucleic acid sequence or a protein. The skilled person will appreciate that the target protein can be generated from a target nucleic acid sequence associated with a disease (e.g., associated, causally related, etc.). In a specific non-limiting example, the target protein is generated from a target nucleic acid sequence (e.g., a genomic target nucleic acid sequence) associated with a neoplasm (e.g., cancer). Numerous chromosomal abnormalities (including translocations and other rearrangements, amplifications, or deletions) have been identified in neoplastic cells, especially in cancer cells, such as B-cell and T-cell leukemias, lymphomas, breast cancer, colon cancer, neurological cancers, and the like. Therefore, in some examples, at least a portion of the target molecule is generated from a nucleic acid sequence (e.g., a genomic target nucleic acid sequence) that is amplified or deleted in at least one subset of cells in a sample.
[0185] In other examples, the target protein is generated from a nucleic acid sequence (e.g., a genomic target nucleic acid sequence) that is deleted (lost) in malignant cells and is a tumor suppressor gene. For example, the p16 region located on chromosome 9p21 (including D9S1749, D9S1747, p16 (INK4A), p14 (ARF), D9S1748, p15 (INK4B), and D9S1752) is deleted in certain bladder cancers. Chromosomal deletions involving the distal region of the short arm of chromosome 1 (which encompasses, for example, SHGC57243, TP73, EGFL3, ABL2, ANGPTL1, and SHGC-1322), and the pericentromeric region of chromosome 19 (e.g., 19p13-19q13) (which encompasses, for example, MAN2B1, ZNF443, ZNF44, CRX, GLTSCR2, and GLTSCR1) are characteristic molecular features of certain types of solid tumors of the central nervous system.
[0186] Those of ordinary skill in the art are aware of numerous other cytogenetic abnormalities associated with neoplastic transformation and / or growth. Target proteins generated by nucleic acid sequences that have been associated with neoplastic transformation and useful in the disclosed methods (e.g., genomic target nucleic acid sequences) also include EGFR genes (7p12; e.g., GENBANK TM Accession number NC-000007, nucleotides 55054219-55242525), C-MYC gene (8q24.21; e.g. GENBANK TM Accession number NC-000008, nucleotides 128817498-128822856), D5S271 (5p15.2), lipoprotein lipase (LPL) gene (8p22; e.g. GENBANK TMAccession number NC-000008, nucleotides 19841058-19869049), RB1 (13q14; e.g. GENBANK TM Accession number NC-000013, nucleotides 47775912-47954023), p53 (17p13.1; e.g. GENBANK TM Accession number NC-000017, complementary strand, nucleotides 7512464-7531642)), N-MYC (2p24; e.g. GENBANK TM Accession number NC-000002, complementary strand, nucleotides 151835231-151854620), CHOP (12q13; e.g. GENBANK TM Accession number NC-000012, complementary strand, nucleotides 56196638-56200567), FUS (16p11.2; e.g. GENBANK TM Accession number NC-000016, nucleotides 31098954-31110601), FKHR (13p14; e.g. GENBANK TM Accession number NC-000013, complementary strand, nucleotides 40027817-40138734), and for example: ALK (2p23; for example GENBANK TM Accession number NC-000002, complementary chain, nucleotides 29269144-29997936), Ig heavy chain, CCND1 (11q13; e.g. GENBANK TM Accession number NC-000011, nucleotide 69165054.69178423), BCL2 (18q21.3; e.g. GENBANK TM Accession number NC-000018, complementary strand, nucleotides 58941559-59137593), BCL6 (3q27; e.g. GENBANK TM Accession number NC-000003, complementary strand, nucleotides 188921859-188946169), MALF1, AP1 (1p32-p31; e.g. GENBANK TM Accession number NC-000001, complementary strand, nucleotides 59019051-59022373), TOP2A (17q21-q22; e.g. GENBANK TM Accession number NC-000017, complementary strand, nucleotides 35798321-35827695), TMPRSS (21q22.3; e.g. GENBANK TMAccession number NC-000021, complementary strand, nucleotides 41758351-41801948), ERG (21q22.3; e.g. GENBANK TM Accession number NC-000021, complementary strand, nucleotides 38675671-38955488); ETV1 (7p21.3; e.g. GENBANK TM Accession number NC-000007, complementary strand, nucleotides 13897379-13995289), EWS (22q12.2; e.g. GENBANK TM Accession number NC-000022, nucleotides 27994271-28026505); FLI1 (11q24.1-q24.3; e.g. GENBANK TM Accession number NC-000011, nucleotides 128069199-128187521), PAX3 (2q35-q37; e.g. GENBANK TM Accession number NC-000002, complementary strand, nucleotides 222772851-222871944), PAX7 (1p36.2-p36.12; e.g. GENBANK TM Accession number NC-000001, nucleotides 18830087-18935219), PTEN (10q23.3; e.g. GENBANK TM Accession number NC-000010, nucleotides 89613175-89716382), AKT2 (19q13.1-q13.2; e.g. GENBANK TM Accession number NC-000019, complementary strand, nucleotides 45431556-45483036), MYCL1 (1p34.2; e.g. GENBANK TM Accession number NC-000001, complementary strand, nucleotides 40133685-40140274), REL (2p13-p12; e.g. GENBANK TM Accession number NC-000002, nucleotides 60962256-61003682) and CSF1R (5q33-q35; e.g. GENBANK TM Accession number NC-000005, complementary strand, nucleotides 149413051-149473128).
[0187] Reagent test kit
[0188] In some embodiments, the present disclosure provides a kit comprising components required for homogenizing, dissociating, and sorting cells, nuclei, or small tissue aggregates from an input sample. For example, the kit may include reagents required to dissociate cells from a specific type of tissue, and the kit may also include a microfluidic device suitable for sorting cells of a specific size.
[0189] Example
[0190] Material
[0191] Mechanical dissociation was performed using an IKA Works Tube Mill control system (0004180001; Staufen im Breisgau, Germany) from IKA-Works. All filters used were from Pluriselect (San Diego, CA). The buffer used was from the following companies: CC1 (950-124; Ventana Medical Systems, Tucson, AZ), autoMACS buffer (130-091-221, Miltenyi Biotech), dPBS (14190, Fisher Scientific, USA). Tween 20 was purchased from Fisher Scientific, USA (AC233362500). The following reagents were purchased from Sigma, USA: spermine tetrachloride (S2876), DAPI (D9542), pepsin (P7012). Proteinase K was purchased from VWR, USA (0706). Tyramide-rhodamine 101 was synthesized internally using chemicals purchased from Sigma. Mouse anti-cytokeratin 8 / 18 antibody (760-4344) and HRP-conjugated goat anti-mouse antibody (760-4310) were from Ventana Medical Systems. Goat anti-mouse antibody conjugated with Alexa 488 or Alexa 647 was purchased from Invitrogen (A-11001).
[0192] Tissue Models and Clinical Samples
[0193] All tissue samples were fixed in 10% neutral buffered formalin for 24 hours at Ventana Medical Systems. Human tonsils were obtained from Northwest Medical Center (Tucson, AZ). Tumor samples were obtained from GLAS / (Winston-Salem, NC http: / / glaswpcopy.wpengine.com / ).
[0194] Example 1-Fixed tissue dissociation
[0195] Fixed tonsil tissue was mechanically dissociated in CC1 buffer (1:5) heated to 85°C in an IKA mixer, incubated at 85°C for 30 minutes, and then mixed again in an IKA mixer (2 minutes, 10 second intervals). The mixed material was exchanged into 1:10 MACS buffer (1:10) and filtered through a 40 μm filter. The filtered dissociated cells were analyzed for yield and size distribution using a Coulter counter.
[0196] For tumor tissue, bulk mechanical dissociation was first performed in MACS buffer in an IKA mixer at a 1:1 tumor:MACS ratio. A small sample of the total homogenate was further mixed in CC1 buffer as described above for tonsils. The mixed material was filtered through a 1 mm x 1 mm metal sieve. CC1 buffer was exchanged for dPBS (1:10) by centrifugation at 300 x g for 1 minute in a tabletop microcentrifuge (Eppendorf); all subsequent liquid exchanges were performed in the same manner. After centrifugation, the pellet was resuspended 1:1 in dPBS containing 1 mg / ml proteinase K and incubated at 50°C for 10 minutes. To quench proteinase K and for further dissociation, the sample was exchanged into 150 mM NaCl, pH 1.5, containing 5 mg / ml pepsin. The pH of the solution was tested with a pH strip and re-adjusted to 1.5-2 using 5 M HCl as needed. The sample was incubated at 37°C for 30 minutes with gentle mixing every 10 minutes. Pepsin was inactivated by adjusting the pH to above 8 with 5M NaOH, and then the solution containing pepsin was exchanged for autoMACS buffer, 1% Tween 20 and 1.5mM spermine tetrachloride (MACS-T-STC). The digested samples were filtered through a 40μm filter using 10ml MACS-T-STC, collected by centrifugation, and resuspended in 500μl MACS-T-STC for storage prior to downstream applications.
[0197] Example 2 - Extraction of single cells from fixed tissues
[0198] Fixed tissue (tonsil or tumor) was first mixed in MACS buffer in an IKA mixer at a 1:1 ratio to generate a homogenate, which could be stored for further use. To extract intact single cells, the following steps were performed:
[0199] 1. Resuspend the homogenate in CC1 buffer at a ratio of 1:5 and heat at 85°C for 30 minutes
[0200] 2. Mix the pre-heated suspension in an IKA mixer (2 times, 2 minutes each, 10 seconds interval)
[0201] 3. Filter the mixed suspension with a 1mm metal sieve
[0202] 4. Filter the filtrate again with a 20um cell filter
[0203] 5. Filter the filtrate with a 10um cell filter
[0204] 6. The filtrate contains mainly single cells while the residue contains fragments of different sizes
[0205] 7. Centrifuge the single cell suspension at 500 g and resuspend in PBS
[0206] Example 3 - Extraction of tissue from paraffin blocks
[0207] Melt the paraffin block containing the tissue at 65°C for 30 minutes and discard the excess wax. Cut the warm tissue into pieces less than 1 mm in size. 2 The tissue fragments were placed in a box with mesh sides. The box was placed in a Leica automated processor and incubated in xylene at 42°C with agitation for 2 hours. The box was exchanged into ethanol and incubated at room temperature with agitation for 1 hour. Two 1.5 L dH 2 O exchange The tissue was rehydrated for 1 hour at room temperature with agitation. The rehydrated tissue was dissociated as described above.
[0208] Example 4 - Sample protocol for obtaining single cell suspensions from primary human tumors (dissociation of cells from tumor samples)
[0209] 1. Before digestion with tumor collagenase, use a scalpel to cut primary human tumors into small pieces and mince thoroughly until they are nearly liquid; make sure to cut the tissue rather than tear it.
[0210] 2. Add collagenase based on the amount of tissue. Collagenase: 9 parts Medium 199 to each 1 part Collagenase / Hyaluronidase. Make up to 200-250 units of collagenase mixture per mL of tumor, adjusting the total volume to the size of the tumor, not to exceed 3-4 mL.
[0211] 3. Transfer the minced tumor in the collagenase solution into a 50 mL conical tube.
[0212] 4. Place the 50 mL conical tube in a 37°C shaker or water bath. If in a shaker, set the motion to 65 rpm for 30 minutes to 1 hour, mixing halfway through. Otherwise, incubate in a water bath for up to 1 hour, mixing every 15 minutes.
[0213] 5. Titrate the mixture 20-25 times using a 5 mL syringe with an 18 or 23 gauge needle. The suspension should pass through the needle.
[0214] 6. Stop the digestion by adding a 2% FBS / HBSS mix in at least an equal amount of the collagenase mix added.
[0215] 7. Then centrifuge the cells at 40g for 30 seconds to separate single cells / fibroblasts from organelles (supernatant will contain single cells, pelleted organelles) or filter through a 40uM nylon mesh cell strainer, then centrifuge at 1000rpm for 5 minutes, aspirate the supernatant, and resuspend the pellet in a 2% FBS / HBSS mixture.
[0216] 8. Wash twice with 2% FBS / HBSS mixture.
[0217] 9. Optional differential sedimentation step to separate cell aggregates from single cells, as described below:
[0218] 9.1 After the first wash with M-199, resuspend the cells in 10 mL of M-199. Shake by hand and let stand for 15 minutes.
[0219] 9.2 Carefully remove the liquid from the cells that have settled to the bottom of the tube and set aside.
[0220] 9.3 Repeat the previous two steps once and proceed. Make sure to count both the supernatant and the pelleted cells.
[0221] 10. After the final wash, suspend the cells and / or freeze the organelles in 5-10 mL of culture medium. Take a 50 μL aliquot into the Coulter Counter. Count the nuclei so you know how many cells are present.
[0222] 11. At the desired density, usually 10 6 Plate cells in 5% IH per 35 mm plate. 6 Freeze unplated cells in freezing medium at 10 cells per ampoule.
[0223] Example 5 -Cell size analysis
[0224] Staining using tyramide signal amplification (TSA)
[0225] The core (3x10 7 The pellets were centrifuged at 300 × g for 2 min and then washed with 0.3 ml 3% HO. 2 O 2After incubation for 15 minutes, the cells were washed three times with PBS containing 0.1% Tween 20, 0.1% BSA. TSA blocking buffer (0.3 ml) was added for 5 minutes, followed by incubation in 0.2 ml primary antibody at 37°C for 30 minutes. The cells were washed three times with PBS containing 0.1% Tween 20, 0.1% BSA, and then resuspended in 0.2 ml goat anti-species antibody conjugated to horseradish peroxidase at 37°C for 30 minutes. The cells were diluted in 1.2 ml 20 μM tyramide-rhodamine 101 and incubated for 5 minutes, followed by 1.2 ml TSA H 2 O 2 The cells were washed three times with PBS containing 0.5% dextran, 0.1% Tween 20, 0.1% BSA and resuspended in MACS-T-STC for storage. Before imaging or flow cytometry, the cells were stained with 3 μM DAPI for 10 minutes.
[0226] Flow cytometry
[0227] Samples were filtered through a 40 μm filter prior to analysis. Analysis and sorting were performed on a Sony SH800 cell sorter. Doublet identification was performed using DAPI pulse width and area.
[0228] Measurement of cell / nucleus yield and size distribution
[0229] Samples were diluted 1:10,000 in Isoton II solution (Beckman Coulter) and analyzed on a Multisizer 4e (Beckman Coulter). Reproducibility was assessed by monitoring the size distribution of particles from different preparations of the same tumor. Size distribution was similarly measured for FACS sorted cells and nuclei.
[0230] Measurement of cell / nucleus size distribution from images
[0231] Dilute the nuclear / cell sample to 10 5 About 100 particles per ml were plated on a glass slide. Bright field images were acquired at 20x magnification across multiple fields (at least 6 per sample) on a Zeiss Axio microscope that had been previously calibrated for pixel:micrometer conversion. Images were thresholded in ImageJ to generate a binary mask that was then used to determine the area of single cells. Area measurements were used to calculate the diameter of all single cells or nuclei in each field of view.
[0232] result
[0233] Analysis of size distribution of dissociated tumor nuclei
[0234] While determining the reproducibility of the yield of our tissue dissociation method using a Coulter counter, we noticed that nuclei from different tumor types were distributed into two populations with similar relative size distributions, such as Figure 5A and 5B Depicted in.
[0235] FACS sorting of dissociated tumor nuclei
[0236] In order to determine whether the tumor nucleus can be analyzed by flow cytometry and sorted using FACS, we will stain the nucleus from the same dissociated tumor sample for cytokeratin.Cytokeratin remains associated with the nucleus and serves as the "nuclear surface marker" of the nucleus of tumor origin.We additionally stain the nucleus with DAPI that reveals DNA content.Fig. 6 shows that for both colon and lung cancer samples, we can identify the cytokeratin positive colony (panel i-iii) containing a higher DNA content than the cytokeratin negative (normal) colony, confirming that the cytokeratin positive nucleus is likely to be derived from tumor cells, while the cytokeratin negative nucleus is likely to be derived from the normal cells in the representative sample.These nuclei are sorted using FACS (the purity check of sorting is shown in the panel iv-v).This experiment provides cytokeratin positive and negative nuclei for analysis by Coulter counter.
[0237] Analysis of size distribution of sorted tumor nuclei
[0238] We next analyzed the size distribution of cytokeratin-positive and cytokeratin-negative nuclei using a Coulter counter. Figure 7 shows the analysis of colon and lung tumor sorted populations obtained from previous experiments, overlaid on Figure 4 The relative size distribution of cytokeratin negative nuclei (dashed line) is aligned with the smaller population, while cytokeratin positive nuclei (solid line) are aligned with the larger population. These data support that the smaller nuclei are derived from normal cells, while the larger nuclei are derived from tumor cells. These data are consistent with the larger size of tumor nuclei relative to immunonuclei seen in histological H&E stained slides (not shown).
[0239] Analysis of size distribution of dissociated tumor cells
[0240] Size-based analysis of cells dissociated from fixed tumors (colon and lung) by Coulter counter reproducibly yielded a bimodal distribution ( Figure 8 ). To better understand the nature of the distribution, EpCAM positive cells dissociated from fixed colon tumors were analyzed. The size of the EpCAM positive cells aligned with the size of the larger cell population within the dissociated tumor cells. Fixed tonsils were also mixed and the size of the extracted single cells was compared to the size of the tumor dissociated cells. The size of the tonsil dissociated cells aligned with the size of the smaller cell population within the dissociated tumor cells ( Figure 8 ).
[0241] Analysis of size distribution of tissue extracted from paraffin
[0242] We next sought to determine whether tissue extracted from paraffin blocks could be dissociated into cells that were similar in size to cells isolated from formalin-fixed tissue that had not been embedded in wax. The purpose of this experiment was to determine whether any size-based particle differentiation could be applied to tissue extracted from wax, such as archived tumor block samples. To test this, we mechanically dissociated formalin-fixed tonsil tissue that had not been embedded in wax and analyzed the cells using a Coulter counter ( Fig. 9 , black). We also extracted tonsil tissue from paraffin blocks (see Methods) and dissociated and analyzed it similarly ( Fig. 9 , gray). These data show that cells isolated from unembedded tissue have a similar size distribution compared to cells isolated from paraffin-extracted tissue.
[0243] Size distribution of nuclei and cells from tonsil and tumor tissues using an orthogonal image-based approach Analysis
[0244] To verify the exact size of nuclei and cells, we performed image-based analysis of nuclei and cells isolated from tonsil and tumor tissue (Figure 16). These data support the size differences between tumor and normal cell particles identified using the Coulter method and provide estimates of the exact diameters that can be used to separate populations.
[0245] Example 6 -Next Generation Sequencing Methodology
[0246] Genomic DNA was purified from each sample using the Roche High Pure FFPET DNA Isolation Kit (Roche, Product Number: 06650767001) following the manufacturer's recommended protocol, except that the proteinase K digestion time was extended to 2 hours at 56° C. in a shaking incubator. The yield of purified gDNA was measured by analysis on a NanoDrop 8000 (ThermoFisher).
[0247] Libraries were constructed from 1 ug of purified input gDNA using the SeqCap EZ HyperCap Workflow User Guide, v1.0 (Roche sequencing protocol), and only brief details are given below to highlight the key steps from the user guide. Extracted gDNA was enzymatically fragmented using the KAPA HyperPlus Library Preparation Kit according to the manufacturer's instructions (Roche sequencing protocol), repaired, and prepared for target enrichment. Specifically, 1 ug of gDNA from each sample was fragmented at 37°C for 40 minutes, end-repaired and A-tailed at 65°C for 30 minutes, and adapters were ligated at 16°C for 16 hours using SeqCap Single Index Adapters (Roche SeqCap Adapter Kits A and B) at a final adapter concentration of 45 pM. No pre-cap LM-PCR amplification was performed on the libraries. Target enrichment was performed using the SeqCap EZ MedExome Enrichment Kit (Roche) following the user guide mentioned above; specifically, 47°C, 16 hours. Post-capture LM-PCR was performed for a total of 14 cycles, instead of the 7 to 9 recommended in the user guide.
[0248] Libraries were pooled, prepared for sequencing, and sequenced on an Illumina HiSeq 2500 instrument using the HiSeq HO V3 kit following the HiSeq 2500 System Guide (Illumina document number 15035786v01).
[0249] Statement of Industrial Applicability
[0250] The present disclosure has industrial applicability in the fields of medicine and diagnostics.
[0251] All U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications mentioned in this specification and / or listed in the Application Data Sheet are incorporated herein by reference in their entirety. Aspects of the embodiments may be modified, if necessary, to employ concepts of the various patents, applications, and publications to provide yet further embodiments.
[0252] Although the present disclosure has been described with reference to some exemplary embodiments, it should be understood that those skilled in the art can devise numerous other modifications and embodiments that will fall within the spirit and scope of the principles of the present disclosure. More particularly, reasonable variations and modifications are possible in the component parts and / or arrangements of the subject combination arrangement within the scope of the foregoing disclosure, the drawings, and the appended claims without departing from the spirit of the present disclosure. In addition to variations and modifications in the component parts and / or arrangements, alternative uses will also be apparent to those skilled in the art.
[0253] Additional embodiments
[0254] Other embodiments 1. A method for separating cells from a tissue sample, comprising: homogenizing a tissue sample to provide a homogenized tissue sample; sorting cells in the homogenized sample by size, wherein the cells are sorted into at least a first and a second cell population, the first cell population being enriched for cells having an average diameter ranging from about 4 μm to about 12 μm, and the second cell population being enriched for cells having an average diameter ranging from about 12 μm to about 50 μm.
[0255] Alternative embodiment 2. The method of another embodiment 1, wherein at least 90% of the cells in the first cell population have an average diameter ranging from 4 μm to 12 μm, and wherein at least 90% of the cells in the second cell population have an average diameter ranging from 12 μm to 50 μm.
[0256] Alternative implementation scheme 3. The method of any of the foregoing additional embodiments, wherein the first cell population is enriched for non-tumor cells, and wherein the second cell population is enriched for tumor cells.
[0257] Alternative Implementation 4. The method of any of the foregoing additional embodiments, wherein the tumor cells have an average diameter ranging from about 12 μm to about 50 μm.
[0258] Alternative embodiment 5. The method of any of the foregoing additional embodiments, wherein the tissue sample is derived from a whole tumor, a portion of a tumor, and / or a lymph node.
[0259] Alternative embodiments 6. The method of any of the foregoing additional embodiments, wherein the tissue sample is derived from residual surgical material or a biopsy sample.
[0260] Alternative embodiments 7. The method of another embodiment 6, wherein the tissue sample is derived from a sample embedded in paraffin.
[0261] Alternative embodiments 8. The method of any one of further embodiments 1 to 6, wherein the homogenized tissue sample is further processed prior to sorting.
[0262] Alternative embodiments 9. In another method of embodiment 8, further processing comprises the steps of digesting proteins within the homogenized sample and filtering the homogenized sample.
[0263] Alternative embodiments 10. The method of any one of further embodiments 1 to 6, wherein sorting the cells in the homogenized sample by size does not require a step of staining the cells.
[0264] Additional embodiments 11.The method of another embodiment 10, wherein cells in the homogenized sample are sorted by size using a microfluidic device.
[0265] Alternative embodiments 12. The method of another embodiment 11, wherein the microfluidic device is a deterministic lateral displacement device.
[0266] Additional embodiments 13. The method of another embodiment 12, wherein cells within the homogenized tissue sample having a critical diameter less than about 12 μm move with convection of the fluid passing through the device, and cells within the homogenized tissue sample having a critical diameter greater than about 12 μm move in a direction dictated by the arrangement of the array.
[0267] Alternative embodiment 14. The method of another embodiment 11, wherein the microfluidic device is a hydrophoretic filtration device.
[0268] Alternative embodiment 15. The method of another embodiment 11, wherein the microfluidic device is a fluid dynamic filtration device.
[0269] Alternative embodiment 16. The method of another embodiment 11, wherein the microfluidic device utilizes inertial focusing in a curved channel.
[0270] Alternative embodiment 17. The method of another embodiment 11, wherein the microfluidic device utilizes inertial focusing in a straight channel.
[0271] Alternative embodiment 18. The method of another embodiment 17, wherein the inertial focusing in the straight channel comprises one of a narrow flow fractionation process or a hydrodynamic diffusion process.
[0272] Alternative embodiments 19. The method of any one of further embodiments 1 to 6 further comprises the step of measuring a first biomarker in cells within the first or second population.
[0273] Alternative embodiments 20. The method of another embodiment 19, wherein the presence of the first biomarker is indicative of cancer.
[0274] Additional embodiments 21. The method of another embodiment 19, wherein the first biomarker is an immune cell marker.
[0275] Alternative embodiment 22. The method of any one of further embodiments 1 to 6, wherein each of the first and second cell populations are independently sequenced using next generation sequencing.
[0276] Alternative embodiment 23.The method of any of further embodiments 1 to 6, wherein the first and second cell populations provide matched tumor and normal cell samples for the patient.
[0277] Another embodiment 24. The method of another embodiment 23, wherein matched tumor and normal cells are analyzed to identify somatic mutations, copy number variations, or other genetic alterations.
[0278] Another embodiment 25. A method for sequencing genomic material in a sample comprises: homogenizing a tissue sample to provide a homogenized tissue sample; and sequencing a first cell population enriched in at least tumor cells.
[0279] Alternative embodiment 26. In another method of embodiment 25, cells in a homogenized sample are sorted using a microfluidic device to provide at least two cell populations, wherein at least 80% of the cells in the first cell population after sorting are tumor cells.
[0280] Alternative embodiment 27. The method of any of further embodiments 25 to 26, wherein at least 80% of the cells within the first cell population have a size greater than 12 μm.
[0281] Alternative embodiment 28. The method of any one of further embodiments 25 to 27, wherein the cells are sorted according to their hydrodynamic size.
[0282] Alternative embodiment 29. The method of any one of further embodiments 25 to 28, wherein the tumor sample is derived from surgical resection.
[0283] Additional embodiments 30. The method of any of embodiments 26 to 29, wherein the microfluidic device does not require staining of the cells prior to sorting.
[0284] Additional embodiments 31. The method of any of embodiments 26 to 30, wherein the microfluidics employs one of deterministic lateral displacement, hydrophoretic filtration, hydrodynamic filtration, inertial focusing in curved channels, and inertial focusing in straight channels.
[0285] Another embodiment 32. The method of any of further embodiments 25 to 31, wherein the first cell population comprises at least 0.05 micrograms of genomic material for sequencing, based on the total weight of the first cell population.
[0286] Additional embodiments 33. The method of any of further embodiments 25 to 31, wherein the first cell population comprises at least 0.1 micrograms of genomic material for sequencing, based on the total weight of the first cell population.
[0287] Another embodiment 34. The method of any one of further embodiments 25 to 33, wherein the method comprises up to 4 cycles of amplification prior to sequencing.
[0288] Another embodiment 35. A method for deriving an enriched population of tumor nuclei and an enriched population of normal nuclei from a tumor sample, comprising dissociating tumor and normal nuclei from the tumor sample; sorting the tumor and normal nuclei by size using a microfluidic sorting device, wherein the microfluidic sorting device does not require a staining or biomarker analysis step before sorting.
[0289] Alternative embodiment 36. The method of another embodiment 35, wherein the enriched population of tumor nuclei comprises at least 85% tumor nuclei; and wherein the enriched population of normal nuclei comprises at least 85% normal nuclei.
[0290] Alternative embodiment 37. The method of any one of further embodiments 35 to 36, wherein the tumor nuclei within the enriched population of tumor nuclei have an average nuclear size greater than 8.5 μm.
[0291] Alternative embodiment 38. The method of any of further embodiments 35 to 37, wherein the normal nuclei within the enriched population of normal nuclei comprise an average nucleus size of less than 8.5 μm.
[0292] Alternative embodiment 39. The method of any one of further embodiments 35 to 38, further comprising the step of separately sequencing the enriched population of tumor nuclei and the enriched population of normal nuclei.
[0293] Another embodiment 40. The method of another embodiment 39, wherein at least one of a somatic mutation, copy number variation, or other genetic alteration is identified in an enriched population of tumor cells.
[0294] Another embodiment 41. The method of any one of further embodiments 35 to 40, wherein the tumor sample is derived from a whole tumor, a portion of a tumor, one or more lymph nodes, and / or a sample embedded in paraffin.
[0295] Another embodiment 42. The method of any one of further embodiments 35 to 41, wherein the tumor sample comprises freshly dissociated tissue.
[0296] Another embodiment 43.A method for treating cancer by identifying cancer subtypes that are responsive to a particular treatment or active pharmaceutical ingredient, wherein the cancer subtype is identified by sequencing a sample enriched for tumor cells; wherein the method comprises: (i) homogenizing an input tissue sample comprising at least one of a tumor, one or more lymph nodes, or blood; and (ii) enriching the sample for tumor cells by sorting tumor cells from normal cells using a size-based sorting device, wherein the size-based sorting device does not require staining of the tumor cells prior to sorting.
[0297] Another embodiment 44. The method of another embodiment 43, wherein the cell population enriched for tumor cells contains a sufficient amount of genomic material to allow for up to four cycles of amplification prior to sequencing. Another embodiment 45. The method of another embodiment 44, wherein up to 2 amplification cycles are performed prior to sequencing.
[0298] Another embodiment 46. The method of another embodiment 44, wherein the amount of genomic material is at least 0.01 micrograms.
[0299] Alternative embodiments 47. The method of another embodiment 44, wherein the amount of genomic material is at least 0.1 microgram.
[0300] Another embodiment 48. The method of another embodiment 44, wherein the amount of genomic material is at least 0.2 micrograms.
[0301] Another embodiment 49. The method of another embodiment 44, wherein the amount of genomic material is at least 0.5 micrograms.
[0302] Another embodiment 50. The method of any one of further embodiments 43 to 49, wherein after identification of the cancer subtype, a course of treatment is provided to the patient from which the sample was derived.
[0303] Another embodiment 51. A method for treating cancer by identifying somatic mutations in tumor cells, comprising: (i) homogenizing a tissue sample derived from a patient; (ii) dissociating cells within the homogenized tissue sample; and (iii) separating tumor cells from normal cells in the dissociated tumor sample using a microfluidic device to provide: (a) a first population enriched in tumor cells, wherein the tumor cells within the first population have an average diameter greater than 12 μm, and (b) a second population enriched in normal cells, wherein the normal cells within the second population have an average diameter less than 12 μm, and wherein the microfluidic device does not require staining or labeling prior to sorting.
[0304] Another embodiment 52.The method of another embodiment 51, wherein the microfluidic device uses one of deterministic lateral displacement, hydrophoretic filtration, hydrodynamic filtration, inertial focusing in curved channels, and inertial focusing in straight channels.
[0305] Another embodiment 53. A method for isolating cells, nuclei, or tissue aggregates from a tissue sample to facilitate downstream analysis, comprising:
[0306] separating cells, nuclei, or tissue aggregates from a tissue sample to provide separate samples;
[0307] The cells, nuclei, or tissue aggregates in the separated sample are sorted by size using a sorting device, wherein the cells, nuclei, or tissue aggregates are sorted into first and second populations, the first population having a first cell, nucleus, or tissue aggregate average diameter and the second population having a second cell, nucleus, or tissue aggregate average diameter.
[0308] Another embodiment 54. The method of another embodiment 53, wherein the first population is enriched for tumor cells, nuclei or tissue aggregates; and the second population is enriched for normal cells, nuclei or tissue aggregates; and wherein the average diameter of the first population is greater than the average diameter of the second population.
[0309] Another embodiment 55. The method of any of embodiments 53 to 54, wherein the sorting device uses one of deterministic lateral displacement, hydrophoretic filtration, fluid dynamic filtration, inertial focusing in curved channels, and inertial focusing in straight channels.
[0310] Another embodiment 56. The method of any of additional embodiments 53 to 55 further comprises the step of performing a genomic analysis on at least one of the first or second populations.
[0311] Alternative embodiments 57. The method of any one of additional embodiments 53 to 56 further comprises the step of performing flow cytometric analysis on at least one of the first or second populations.
[0312] Another embodiment 58. The method of any of further embodiments 53 to 57, further comprising the step of staining at least one of the first or second populations for the presence of at least one biomarker.
[0313] Another embodiment 59. A method for separating cells from a fresh tissue sample, comprising: homogenizing the fresh tissue sample to provide a homogenized tissue sample;
[0314] Cells in a homogenized fresh tumor sample are sorted by size, wherein the cells are sorted into first and second cell populations, the first cell population is enriched for cells having an average diameter ranging from about 6 μm to 12 μm, and the second cell population is enriched for cells having an average diameter greater than 12 μm.
[0315] Another embodiment 60. The method of another embodiment 59, wherein the first cell population is enriched for non-tumor cells and wherein the second cell population is enriched for tumor cells.
[0316] Additional embodiments 61. The method of any one of further embodiments 59 to 60, wherein the fresh tumor sample is derived from a fresh whole tumor, a fresh portion of a tumor, and / or a fresh lymph node.
[0317] Another embodiment 62. The method of any one of further embodiments 59 to 60, wherein the fresh tumor sample is derived from fresh residual surgical material or a fresh biopsy sample.
[0318] Alternative embodiments 63. The method of any of embodiments 59 to 62, wherein the sorting device does not require a step of staining the cells.
[0319] Another embodiment 64. The method of another embodiment 63, wherein the sorting device is a microfluidic device.
[0320] Another embodiment 65. The method of another embodiment 64, wherein the microfluidic device is a deterministic lateral displacement device.
[0321] Alternative embodiments 66. The method of another embodiment 65, wherein cells having a diameter less than 12 μm within the homogenized fresh tumor sample move with the convection of the fluid passing through the deterministic lateral displacement device, and cells having a critical diameter greater than 12 μm within the homogenized sample move in a direction dictated by the arrangement of the array.
[0322] Alternative embodiments 67. The method of another embodiment 64, wherein the microfluidic device is a hydrophoretic filtration device.
[0323] Alternative embodiments 68. The method of another embodiment 64, wherein the microfluidic device is a fluid dynamic filtration device.
[0324] Alternative embodiments 69. The method of another embodiment 64, wherein the microfluidic device utilizes inertial focusing in a curved channel.
[0325] Alternative embodiments 70.The method of another embodiment 64, wherein the microfluidic device utilizes inertial focusing in a straight channel.
[0326] Additional embodiments 71. The method of another embodiment 70, wherein the inertial focusing in the straight channel comprises one of a narrow flow fractionation process or a hydrodynamic diffusion process.
[0327] Alternative embodiments 72. The method of any one of further embodiments 59 to 62 further comprises the step of measuring a first biomarker on cells within the first or second population.
[0328] Alternative embodiments 73. The method of another embodiment 72, wherein the presence of the first biomarker is indicative of cancer.
[0329] Alternative embodiments 74. The method of another embodiment 72, wherein the first biomarker is an immune cell marker.
[0330] Alternative embodiments 75. A method for separating cells from a tissue sample comprises: homogenizing a tumor sample to provide a homogenized tissue sample; sorting cells in the homogenized tissue sample by size, wherein the cells are sorted into first and second cell populations, the first cell population being enriched for cells having an average diameter of less than 12 μm, and the second cell population being enriched for cells having an average diameter of greater than 12 μm.
[0331] Alternative embodiments 76. A composition enriched for tumor cells, the tumor cells having a size greater than 12 μm, wherein the tumor cells are separated from normal cells without first staining the tumor or normal cells.
[0332] Alternative embodiments 77. The composition of another embodiment 76, wherein at least 50% of the composition comprises tumor cells.
[0333] Alternative embodiments 78. The composition of another embodiment 76, wherein at least 65% of the composition comprises tumor cells.
[0334] Alternative embodiments 79. The composition of another embodiment 76, wherein at least 80% of the composition comprises tumor cells.
[0335] Another embodiment 80. The composition of another embodiment 76, wherein at least 95% of the composition comprises tumor cells.
[0336] Additional embodiments 81.A kit comprising a first cell population and a second cell population, wherein the first cell population is substantially enriched for tumor cells having a size greater than 12 μm, and the second cell population is substantially enriched for normal cells having a size less than 12 μm, the first and second cell populations are derived from the same tumor sample, and wherein the tumor cells and normal cells are unstained.
[0337] Alternative embodiments 82. A method of testing for genetic abnormalities comprising performing genomic analysis on each of the cell populations of another embodiment 81.
[0338] Alternative embodiments 83. The method of another embodiment 82 further comprises the step of identifying at least one biomarker in the cell population of another embodiment 81.
[0339] Alternative embodiments 84. A device for separating cells derived from a tissue sample, the device comprising one or more of a column, an obstacle, or an obstacle, so that cells with a size smaller than 12 μm flow in a first direction, and cells with a size larger than 12 μm flow in a second direction.
[0340] Alternative embodiments 85. A composition enriched for tumor nuclei having a size greater than 8.5 μm, wherein the tumor nuclei are separated from normal nuclei without first staining the tumor or normal nuclei.
[0341] Alternative embodiments 86. The composition of another embodiment 85, wherein at least 50% of the composition comprises tumor nuclei.
[0342] Alternative embodiments 87. The composition of another embodiment 85, wherein at least 65% of the composition comprises tumor nuclei.
[0343] Alternative embodiments 88. The composition of another embodiment 85, wherein at least 80% of the composition comprises tumor nuclei.
[0344] Alternative embodiments 89. The composition of another embodiment 85, wherein at least 95% of the composition comprises tumor nuclei.
[0345] Another embodiment 90. A kit comprising a first nuclear population substantially enriched for tumor nuclei having a size greater than 8.5 μm and a second nuclear population substantially enriched for normal nuclei having a size less than 8.5 μm, the first and second nuclear populations being derived from the same tumor sample, and wherein the tumor nuclei and normal nuclei are unstained.
[0346] Another embodiment 91.A method of testing for genetic abnormalities comprising performing genomic analysis on each of the cell populations of further embodiment 90.
[0347] Another embodiment 92. A device for separating nuclei derived from a tumor sample, the device comprising one or more of a pillar, a barrier, or a barrier such that nuclei having a size less than 8.5 μm flow in a first direction and nuclei having a size greater than 8.5 μm flow in a second direction.
[0348] In summary, the present invention includes but is not limited to the following:
[0349] 1. A method for separating cell particles from a tissue sample, comprising: (i) homogenizing the tissue sample to provide a homogenized sample; and (ii) sorting the cell particles in the homogenized tissue sample into at least a first cell particle population and a second cell particle population by size.
[0350] 2. The method of claim 1 , wherein the cell particles comprise cells.
[0351] 3. The method of any of the preceding items, wherein the cell particles include cell nuclei.
[0352] 4. The method of any of the preceding items, wherein the second population of cell particles comprises cell particles derived from tumor cells.
[0353] 5. The method of claim 4, wherein the cell particles derived from tumor cells have an average diameter ranging from about 12 μm to about 50 μm or from about 8.5 μm to about 30 μm.
[0354] 6. The method of claim 5, wherein the tumor cells are derived from at least one of an intact tumor, a portion of a tumor, a metastatic tumor, a portion of a metastatic tumor, or a lymph node.
[0355] 7. The method of any of the preceding items, wherein the tissue sample is derived from at least one of residual surgical material or a biopsy sample.
[0356] 8. The method of any of the preceding items, wherein the tissue sample is a tissue sample fixed in a cross-linking solution.
[0357] 9. The method of any of the preceding items, wherein the tissue sample is derived from a sample embedded in paraffin.
[0358] 10. The method of any of the preceding items, wherein the homogenized tissue sample is further processed before sorting, wherein the further processing comprises at least one of digesting proteins within the homogenized sample, heating the sample, or filtering the homogenized sample.
[0359] 11. The method of any of the preceding items, wherein sorting the cell particles in the homogenized sample by size does not require a step of staining the cell particles.
[0360] 12. The method of any of the preceding items, wherein a microfluidic device is used to sort cell particles within a homogenized tissue sample.
[0361] 13. The method of claim 12, wherein the microfluidic device is a deterministic lateral displacement device.
[0362] 14. The method of claim 13, wherein cell particles having a critical diameter of less than about 12 μm within the homogenized sample move with convection of the fluid passing through the deterministic lateral displacement device, and cells having a critical diameter of greater than about 12 μm within the homogenized sample move in a direction specified by the arrangement of the array.
[0363] 15. The method of claim 12, wherein the microfluidic device is a hydrophoretic filtration device.
[0364] 16. The method of claim 12, wherein the microfluidic device is a fluid dynamic filtration device.
[0365] 17. The method of claim 12, wherein the microfluidic device utilizes inertial focusing in a curved channel.
[0366] 18. The method of claim 12, wherein the microfluidic device utilizes inertial focusing in a straight channel.
[0367] 19. The method of claim 18, wherein the inertial focusing in the straight channel comprises one of a narrow flow fractionation process or a fluid dynamic diffusion process.
[0368] 20. The method of any of the preceding items, further comprising the step of measuring a first biomarker in cell particles within at least the first or second population.
[0369] 21. The method of claim 20, wherein the presence of the first biomarker indicates cancer.
[0370] 22. The method of claim 20, wherein the first biomarker is an immune cell marker.
[0371] 23. The method of any of the preceding items, wherein each of the first and second cell particle populations are independently sequenced using next generation sequencing.
[0372] 24. The method of any of the preceding items, wherein each of the first and second populations of cell particles are analyzed independently using flow cytometry.
[0373] 25. The method of any of the preceding items, wherein the first and second populations of cell particles provide matched tumor and normal samples for a patient.
[0374] 26. The method of claim 25, wherein matched tumor and normal samples are analyzed to identify somatic mutations, copy number variations, or other genetic alterations.
[0375] 27. The method of any of the preceding items, further comprising analyzing the first and second cell particle populations for RNA biomarkers.
[0376] 28. The method of any one of items 1 to 26, further comprising analyzing the first and second cell particle populations for protein biomarkers.
[0377] 29. A method for separating cells from a tissue sample, comprising:
[0378] homogenizing the tissue sample to provide a homogenized tissue sample;
[0379] Cells in a homogenized tissue sample are sorted by size, wherein the cells are sorted into at least a first cell population enriched in cells having an average diameter of less than 12 μm and a second cell population enriched in cells having an average diameter of greater than 12 μm, and wherein the cells within the homogenized tissue sample are sorted using a microfluidic device.
[0380] 30. The method of claim 29, wherein the microfluidic device is selected from the group consisting of a deterministic lateral displacement device, a hydrophobic filtration device, a fluid dynamic filtration device, a microfluidic device utilizing inertial focusing in a curved channel, and a microfluidic device utilizing inertial focusing in a straight channel.
[0381] 31. The method of any one of items 29 to 30, wherein the microfluidic device does not require staining of cells prior to sorting.
[0382] 32. The method of any one of items 29 to 31, further comprising analyzing at least one of an RNA biomarker or a protein biomarker in the first or second cell population.
[0383] 33. The method of any one of items 29 to 32, further comprising sequencing at least one of the first or second cell populations.
[0384] 34. The method of claim 33, wherein the amount of genomic material available for sequencing in the first or second cell population is at least 0.05 micrograms.
[0385] 35. The method of claim 34, wherein the amount of genomic material is at least 0.1 microgram.
[0386] 36. The method of any one of items 33 to 35, wherein up to four amplification cycles are performed prior to sequencing.
[0387] 37. The method of any one of items 33 to 36, wherein sequencing is performed using next generation sequencing.
[0388] 38. The method of any one of items 29 to 37, wherein the first and second cell populations provide matched tumor and normal samples for the patient.
[0389] 39. The method of any one of items 29 to 38, wherein the first cell population is enriched in normal cells and the second cell population is enriched in tumor cells.
[0390] 40. A method for deriving at least an enriched population of tumor nuclei and an enriched population of normal nuclei from a self-tissue sample, comprising: dissociating tumor and normal nuclei from a self-tissue sample; and sorting tumor and normal nuclei by size using a microfluidic sorting device; wherein the normal nuclei in the enriched population of normal nuclei have an average nuclear size of less than 8.5 μm; and wherein the tumor nuclei in the enriched population of tumor nuclei have an average nuclear size of greater than 8.5 μm.
[0391] 41. The method of claim 40, wherein the microfluidic sorting device does not require a staining or biomarker analysis step prior to sorting.
[0392] 42. The method of claim 40 or claim 41, further comprising analyzing at least one of an RNA biomarker or a protein biomarker in an enriched population of tumor nuclei or an enriched population or normal nuclei.
[0393] 43. The method of any one of items 40 to 42, further comprising sequencing at least one of the enriched population of tumor nuclei or the enriched population of normal nuclei.
[0394] 44. The method of claim 43, wherein the amount of genomic material available for sequencing in the first or second cell population is at least 0.05 micrograms.
[0395] 45. The method of claim 44, wherein the amount of genomic material is at least 0.1 microgram.
[0396] 46. The method of any one of items 40 to 45, further comprising analyzing at least one of the enriched population of tumor nuclei or the enriched population of normal nuclei using flow cytometry.
[0397] 47. The method of any one of items 40 to 46, wherein the tissue sample is derived from at least one of an intact tumor, a portion of a tumor, a metastatic tumor, a portion of a metastatic tumor, or a lymph node.
[0398] 48. The method of any one of items 40 to 47, wherein the tissue sample is derived from at least one of residual surgical material or a biopsy sample.
[0399] 49. The method of any one of items 40 to 48, wherein the tissue sample is a tissue sample fixed in a cross-linking solution.
[0400] 50. The method of any one of items 40 to 49, wherein the tissue sample is derived from a sample embedded in paraffin.
[0401] 51. A method for separating cell particles from a tissue sample, comprising: (i) homogenizing the tissue sample to provide a homogenized sample; and (ii) sorting the cell particles within the homogenized tissue sample into at least a first population and a second population, wherein the cell particles are sorted within a microfluidic device and wherein no staining is performed prior to sorting.
[0402] 52. The method of claim 51, wherein the cell particles are cells, and wherein the first population comprises normal cells and the second population comprises tumor cells.
[0403] 53. The method of claim 52, wherein normal cells have an average diameter less than 12 μm and tumor cells have an average diameter greater than 12 μm.
[0404] 54. The method of claim 51, wherein the cell particles are nuclei, and wherein the first population comprises normal nuclei and the second population comprises tumor nuclei.
[0405] 55. The method of claim 53, wherein normal nuclei have an average diameter less than 8.5 μm and tumor nuclei have an average diameter greater than 8.5 μm.
[0406] 56. A method for separating cell particles from a tissue sample, comprising: (i) homogenizing the tissue sample to provide a homogenized sample; and (ii) sorting the cell particles within the homogenized tissue sample into at least a first population and a second population, wherein the cell particles are sorted within a microfluidic device and wherein staining is performed prior to sorting.
[0407] 57. The method of claim 56, wherein the cell particles are cells, and wherein the first population comprises normal cells and the second population comprises tumor cells.
[0408] 58. The method of claim 57, wherein normal cells have an average diameter less than 12 μm and tumor cells have an average diameter greater than 12 μm.
[0409] 59. The method of claim 56, wherein the cell particles are nuclei, and wherein the first population comprises normal nuclei and the second population comprises tumor nuclei.
[0410] 60. The method of claim 59, wherein normal nuclei have an average diameter less than 8.5 μm and tumor nuclei have an average diameter greater than 8.5 μm.
Claims
1. A method for separating cell particles from a tissue sample, the method comprising: (i) homogenizing the tissue sample to provide a homogenized sample; and (ii) sorting the cell particles in the homogenized tissue sample into at least a first cell particle population and a second cell particle population by size, wherein the cell particles are cell nuclei, and wherein the cell particles are not stained, marked or labeled before or during the sorting step.
2. The method of claim 1, wherein the second population of cell particles comprises cell particles derived from tumor cells. 3 . The method of claim 2 , wherein the cell particles derived from tumor cells have an average diameter ranging from about 12 μm to about 50 μm or from about 8.5 μm to about 30 μm.
4. The method of any one of claims 2-4, wherein the tumor cell is derived from at least one of a complete tumor, a portion of a tumor, a metastatic tumor, a portion of a metastatic tumor, or a lymph node.
5. The method of any one of claims 1-4, wherein the tissue sample is derived from at least one of residual surgical material or a biopsy sample.
6. The method according to any one of the preceding claims, wherein the tissue sample is a tissue sample fixed in a cross-linking solution.
7. The method according to any one of the preceding claims, wherein the tissue sample is derived from a sample embedded in paraffin.
8. The method according to any one of the preceding claims, wherein the homogenized sample is further processed before sorting, wherein the further processing comprises at least one of digesting proteins within the homogenized sample, heating the sample, or filtering the homogenized sample.
9. The method according to any one of the preceding claims, wherein the cell particles within the homogenized tissue sample are sorted using a microfluidic device.
10. The method of claim 9, wherein the microfluidic device is a deterministic lateral displacement device.
